

Published in final edited form as:

New J Chem. 2005 January 1; 29(2): 291–305.

The C- and N-Terminal Residues of Synthetic Heptapeptide Ion Channels Influence Transport Efficacy Through Phospholipid Bilayers

Natasha Djedović[†], Riccardo Ferdani[†], Egan Harder[‡], Jolanta Pajewska[†], Robert Pajewski[†], Michelle E. Weber[†], Paul H. Schlesinger[‡], and George W. Gokel^{†,§}

[§]Department of Chemistry, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8103, St. Louis, MO 63110 U. S. A.

[†]Department of Molecular Biology & Pharmacology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8103, St. Louis, MO 63110 U. S. A.

[‡]Department of Cell Biology and Physiology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8103, St. Louis, MO 63110 U. S. A.

Abstract

The synthetic peptide, R₂N-COCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OR', was shown to be selective for Cl⁻ over K⁺ when R is *n*-octadecyl and R' is benzyl. Nineteen heptapeptides have now been prepared in which the *N*-terminal and *C*-terminal residues have been varied. All of the *N*-terminal residues are dialkyl but the *C*-terminal chains are esters, 2° amides, or 3° amides. The compounds having varied *N*-terminal anchors and *C*-terminal benzyl groups are as follows: **1**, R = *n*-propyl; **2**, R = *n*-hexyl; **3**, R = *n*-octyl; **4**, R = *n*-decyl; **5**, R = *n*-dodecyl; **6**, R = *n*-tetradecyl; **7**, R = *n*-hexadecyl; **8**, R = *n*-octadecyl. Compounds **9-19** have R = *n*-octadecyl and *C*-terminal residues as follows: **9**, OR' = OCH₂CH₃; **10**, OR' = OCH(CH₃)₂; **11**, OR' = O(CH₂)₆CH₃; **12**, OR' = OCH₂-*c*-C₆H₁₁; **13**, OR' = O(CH₂)₉CH₃; **14**, OR' = O(CH₂)₁₇CH₃; **15**, NR'₂ = N[(CH₂)₆CH₃]₂; **16**, NHR' = NH(CH₂)₉CH₃; **17**, NR'₂ = N[(CH₂)₉CH₃]₂; **18**, NHR' = NH(CH₂)₁₇CH₃; **19**, NR'₂ = N[(CH₂)₁₇CH₃]₂. The highest anion transport activities were observed as follows. For the benzyl esters whose *N*-terminal residues were varied, *i.e.* **1-8**, compound **3** was most active. For the C₁₈ anchored esters **10-14**, *n*-heptyl ester **11** was most active. For the C₁₈ anchored, *C*-terminal amides **15-19**, di-*n*-decylamide **17** was most active. It was concluded that both the *C*- and *N*-terminal anchors were important for channel function in the bilayer but that activity was lost unless only one of the two anchoring groups was dominant.

Introduction

Cell biologists, neuroscientists, and others within the biological community have extensively studied channel proteins for more than a century. Much about their properties and behavior has been well characterized and recorded. Indeed, several monographs are available that describe channel function.¹ During the past decade, the field has been revolutionized by solid state studies that have revealed the structures of cation,^{2,3} anion,⁴ water,⁵ and pressure-sensitive channels.⁶ The importance of this work is apparent from the award of the 2003 Nobel Prize in Chemistry to Agre⁷ and MacKinnon.⁸

Proofs to G. W. Gokel, Department of Molecular Biology & Pharmacology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8103, St. Louis, MO 63110 USA, Tel. 314/362-9297, FAX 314/362-9298 or 7058, E-mail: E-mail: ggokel@molecool.wustl.edu.

During the past two decades, our understanding of what compounds may function as channels has also expanded. For example, Reusch and coworkers showed in 1988⁹ that bacteria used a poly- α -hydroxybutyrate/calcium polyphosphate channel. Sophisticated function by such a simple chemical structure was greeted initially by skepticism, but classical total synthesis by Seebach and coworkers conclusively demonstrated both structure and function.¹⁰

Synthetic peptides that show ion channel activity have been constructed *de novo*. Montal and coworkers demonstrated channel-like activity from compounds that they called *synporins*.¹¹ These template-assembled synthetic proteins (TASP, four-helix bundles) showed channel activity.¹² At about the same time, DeGrado and coworkers reported the design of simple peptides (“minimalist proteins”)¹³ that functioned as cation-conducting channels.¹⁴

Tabushi reported the first channel compound that was designed by chemical conceptualization rather than from peptides. It used a cyclodextrin head group and was designed to penetrate only one bilayer of the phospholipid membrane. Transmembrane transport of cobalt cation was demonstrated.¹⁵ Other early synthetic ion channels were reported by Fyles,¹⁶ Lehn,¹⁷ Menger,¹⁸ Nolte,¹⁹ Kobuke,²⁰ and by our group.²¹ Among these, when transport was demonstrated, it involved cations. A number of other examples, including those reported by Voyer,²² Matile,²³ and Koert,²⁴ have appeared since and the expanding progress in this field has been reviewed.^{25,26,27,28} The field of synthetic, anion-conducting channels has lagged well behind the development of synthetic cation channels. Of course, this has also been true of anion complexation by synthetic host molecules.²⁹ To our knowledge, chloride or anion transport activity is limited to only a few synthetic examples: Tomich’s synthetic peptides,³⁰ the oligophenoxyacetamides,³¹ our membrane-anchored heptapeptides,³² and Matile’s recent anion channel.³³ We now report that within the anion-channel-forming synthetic framework we have developed, the *C*-terminal and *N*-terminal anchors significantly influence the rates and selectivity of ion transport through a phospholipid bilayer membrane.

Results and Discussion

A phospholipid-mimetic anchor

Our design of the synthetic cation channel compounds we call hydraphiles was based on the notion that a single molecular span would transcend both leaflets of the phospholipid bilayer and lead to a functional channel.³⁴ In contrast to this crown ether-based design, the formation of pores from the antifungals amphotericin and nystatin suggested that a single, membrane-leaflet span might produce a functional channel.³⁵ We considered that a simple or primitive channel must have been much like a phospholipid membrane monomer. This demanded a combination of hydrophobic anchor chains and a mimic of the acyl glycerol “midpolar regime” of bilayer lipids. Both challenges could be met by reaction of a dialkylamine with diglycolic anhydride. Thus, when dioctadecylamine was heated (reflux, 48 h) with diglycolic anhydride in toluene, only $(C_{18}H_{37})_2NCOCH_2OCH_2COOH$ was isolated (87% after crystallization). This readily accessible subunit provides both the hydrophobic chains and the carbonyl groups required to mimic the portion of a phospholipid that is well within the bilayer structure. It is also versatile as the chain lengths (R^1 and R^2) may be varied and may be either the same or different. The anchor unit, $R^1R^2NCOCH_2OCH_2COOH$, can be attached to the *N*-terminal residue of any peptide by standard coupling methods.

Design of the peptide sequence

The peptide sequence chosen was based in part on the observation that a proline is conserved in the presumed selectivity filter of the CIC family of proteins. The sequence is typically G-X-X-P. The sequence Gly-Gly-Gly-Pro (GGGP) in our design meets this condition. Three additional glycines incorporated at the *C*-terminal end of GGGP give a symmetrical

heptapeptide, GGGPGGG. Molecular models suggest that the C- and N-terminal ends of this bent heptapeptide will be separated by 7-8 Å, depending on overall flexibility. The V-shaped opening is therefore wide enough to accommodate a hydrated chloride anion, which is calculated to be ~6.5 Å in diameter.³⁶ A model of H₂N-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₃ in the tube metaphor, created by energy minimization in Gaussian 98W, is shown in Figure 1.

The range of compounds studied

Carboxyl groups are typically ionized at physiologic pH. If not substituted, the free carboxyl group in GGGPGGG would make the C-terminus of the molecule very polar. The C-terminal ester, initially benzyl, was therefore intended to “cap” the heptapeptide. Ultimately, variations in the C-terminal ester were prepared that included both esters and amides. It was anticipated that a C-terminal amide would differ from an ester in stability, polarity, and steric and conformational features. Nineteen synthetic Gly-Gly-Gly-Pro-Gly-Gly-Gly derivatives were prepared for this report. The C- and N-terminal groups were varied. The model shown above was simplified to a C-terminal methyl ester and N-terminal amine to simplify the calculation. The molecular weight of the model shown (not synthesized) is 471 Da. The simplest structure prepared for this study is **1** (C3-benzyl), which has an N-terminal dipropylamine residue and a C-terminal benzyl ester (mw 746 Da). The largest ester residue, **14** (C18-octadecyl), has a molecular weight of 1328 Da. The corresponding bis(octadecyl)amide, **16**, has a weight of 1579 Da. The range of molecular weights for these heptapeptides is therefore two-fold. The structures are identified in Table 1.

Hydrophobic/hydrophilic balance

The graph in Figure 2 shows the calculated octanol/water partition coefficients (logP) for **1-8**. The partition coefficient P is an estimate of the affinity a compound has for a bilayer or nonpolar environment (represented by octanol). Equal (*i.e.* 1/1) distribution between the two phases would give a partition coefficient of 1, the log₁₀ of which is 0. We expected all of these compounds to favor octanol, as the graph clearly shows. Increasing the N-terminal chain length further favors solubility in the organic phase as shown by the positive slopes of both lines in Figure 2. The data presented were obtained from the AlogP website (<http://146.107.217.178/lab/alogps/index.html>).

The upper line in Figure 2 shows the effect of changing the C-terminal residue while maintaining octadecyl N-terminal chains (**1-8**). Note that in the latter case, heptyl, cyclohexylmethyl, and benzyl all possess 7 carbons and essentially overlap in the graph. Hydrophobicity changes greatly in compounds **8-14**, in which the N-terminal alkyl chains are varied and the C-terminal group is always benzyl. The “chain length” designation in the graph of Figure 2 reflects each of the two chain lengths accounting for the steep slope. In both cases, the calculated log P values were fitted by a straight line having $r^2 \geq 0.98$. In short, these calculations confirm expectations about the hydrophobicity properties of these molecules.

Synthesis of 1-19

The compounds prepared for this study were constructed in essentially the four steps shown in Scheme 1. The first stage is the addition of a dialkylamine to diglycolic anhydride (see above). Compounds **8-19**, each of which has twin octadecyl chains at its N-terminus, were begun in this way. Compounds **1-7** were prepared similarly but the procedure was varied to account for the lower boiling points of the smaller dialkylamines. For example, the reaction of diglycolic anhydride and dipropylamine used refluxing THF rather than toluene (see Experimental Section for additional details). Isolated yields for R₂NCOCH₂OCH₂COOH derivatives were in the range 75-100%.

Once formed, $R_2NCOCH_2OCH_2COOH$ was coupled with $TsOH \cdot H_2N-Gly-Gly-Gly-OCH_2Ph$ and mediated by $Me_2N(CH_2)_3N=C=NEt \cdot HCl$ (EDCI) and *N*-hydroxybenzotriazole (HOBT) under standard conditions. The resulting tripeptide was debenzylated by hydrogenolysis (H_2 , Pd/C) to give $R_2NCOCH_2OCH_2CO-Gly-Gly-Gly-OH$. A second coupling, using EDCI and HOBT with $HCl \cdot H-Pro-Gly-Gly-Gly-OCH_2Ph$, gave the amphiphilic heptapeptide ester. This approach was used for the preparation of **1-8**. Esters **9-12** were prepared by coupling $R_2NCOCH_2OCH_2CONH-GGG-OH$ with the $H-PGGG-OR'$ fragment. Decyl and octadecyl ester derivatives **13** and **14** were prepared by coupling $R_2NCOCH_2OCH_2CONH-GGGPGGG-OH$ with $R'OH$. Hydrogenolysis of benzyl ester **1** gave the free acid, which was coupled (DCCI, DMAP) to an alcohol or amine to afford **9-19**. Standard coupling conditions (EDCI, HOBT, Et_3N in CH_2Cl_2) between $[CH_3(CH_2)_{17}]_2NCOCH_2OCH_2CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OH$ and the alkyl or dialkylamine gave the **15-19** in 30-40% yield.

Assay of channel activity

The success of a channel design is demonstrated only by function. Methods used previously in our lab and by others include fluorescence measurements of a pH sensitive dye,¹⁶ competition with proton transport,^{37,38} and NMR methods.³⁹ Planar bilayer conductance measurements are labor intensive but provide direct information about both transport and selectivity.^{30a} We have used NMR methods to study Na^+ transport⁴⁰ in the crown ether-based hydrophile cation channels.³² Direct NMR observation of ^{35}Cl and ^{37}Cl , both of which have spin 3/2, are less useful for this assay. We therefore elaborated a method previously described by one of us⁴¹ and by others⁴² that uses chloride-selective electrodes to measure chloride efflux from liposomes. The liposomes required for these studies were prepared from 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-*sn*-glycero-3-phosphate (DOPA) (7:3 w/w) as previously reported.⁴¹ The size distribution was assayed by light scattering after passing through a 200 nm filter and found to be narrow and slightly larger than the specified filter size.

Chloride release was monitored directly by using an Accumet Chloride Combination Electrode. The electrode was introduced into the liposome suspension and the transporter was added, typically as a ~9 mM solution in 2-propanol. In no case was more than 20 μL of 2-propanol added to the liposome suspension. When monitoring was complete, the vesicles were lysed by addition of 2% aqueous Triton X100 (100 μL). The data were normalized to this final value.

Chloride ion release as a function of the N-terminal anchor chain length


Figure 3 shows the results obtained for chloride release from phospholipid vesicles mediated by compounds **1-8**. The period of observation was at least 1500 seconds and each trace is the average of three separate experiments. The method assesses the ability of the channel to insert into the bilayer and induce ion release. Once a functional channel inserts in the bilayer, the liposomes empty within a few seconds.⁴¹ The black trace just below the "C14" label shows data for the C18-benzyl channel (**8**, "SCMTR").³² As the anchor chain is shortened, the release of chloride increases in a systematic way until the twin anchor chains pass *n*-octyl (**3**). The chloride release traces for C14-benzyl (**6**) and C3-benzyl (**1**) are nearly superimposed on those for C16-benzyl (**7**) and C18-benzyl (**8**).

It seems counterintuitive that a decrease in anchor chain length would lead to an increase in ion transport. Such an enhancement in transport would be more reasonable if ion selectivity, pore structure, and stoichiometry were affected by the differences in chain length. We do not have direct evidence to show whether or not changes in pore stoichiometry occur, but we have determined ion selectivity for C10-benzyl (**4**) and C18-benzyl (**8**) channels. The latter (**8**) is >10-fold selective for Cl^- over K^+ but the former transports both chloride and cations with

equal efficacy. Thus, the higher release rates may be attributed to a less selective, and higher conducting, pore.

Carboxyfluorescein release from vesicles

Anion release from the compounds studied above was confirmed by use of the fluorescent dye carboxyfluorescein (CF). In this technique, vesicles are formed in the presence of the dye. The external solution is then exchanged by using a size exclusion column to remove CF. The concentration of dye within the vesicles is high enough that self-quenching occurs. Addition of **8** or its relatives leads to release of the dye. As release proceeds, the concentration of CF is low enough in the external medium that self-quenching does not occur and the dye's fluorescence is readily detectable. Quantitative measurement of the fluorescence at $\lambda = 520$ nm permitted the release rate to be determined.



Carboxyfluorescein is larger than hydrated chloride. Judging from CPK and computer models, CF is $\sim 10 \text{ \AA} \times 10 \text{ \AA}$. Its thickness depends on the position of the dicarboxyphenyl group with respect to three fused rings. An opening formed by dimerization of the heptapeptides would have to open relatively little (*i.e.* “breathe”) to permit its passage.

The *N*-terminal anchor chain-dependent release of CF is shown in Figure 4. The ionophores that induced the behavior shown are, from the top trace to the bottom, **3** (C8-benzyl), **4** (C10-benzyl), **5** (C12-benzyl), **6** (C14-benzyl), **7** (C16-benzyl), and **8** (C18-benzyl). All are benzyl esters and their respective *N*-terminal, twin alkyl chain lengths are each 8, 10, 12, 14, 16, and 18 carbon atoms.

Although many of the same compounds are involved, there are several differences between these results and those shown in Figure 3. First, this study is not as extensive as that presented in Figure 3, which shows results for **1-8**. Figure 4 records results only for compounds **3-8**. Figure 3 records the release of Cl^- , monitored over a period of 1500 s. The analysis used a chloride-selective electrode. The data in Figure 4 were obtained by fluorescence of CF over a period of ~ 6000 s, but data for only the first 300 s are reported. The Cl^- and CF experiments were done using different ratios of lipid to ionophore and CF release reached a plateau very rapidly. In the chloride release experiments, the typical lipid concentration was 0.31 mM and the compound was added to a final concentration of $65 \mu\text{M}$. In the CF dequenching experiments, an excess of ionophore was present ($[\text{lipids}] = 3.5 \mu\text{M}$, $[\text{compound}] = 10 \mu\text{M}$). The lipid:ionophore ratios in the experiments that monitored Cl^- or CF release are different. The experimental methods use different concentrations of ionophore and inorganic or organic anion. The detection involves an ion-selective electrode in one case and fluorescence in the other. These differences are required to obtain both reproducible results over a broad concentration range and good signal to noise ratios. Notwithstanding the differences, the trends apparent for the release of the Cl^- or CF anion are remarkably similar.

An additional set of studies was undertaken with the C10-benzyl (**4**) and C18-benzyl (**8**) channels. The concentration dependence of the CF release from liposomes mediated by **4** and by **8** was studied. As before, the CF fluorescence was monitored at $\lambda = 520$ nm. The concentration range studied for **8** was $12.3\text{-}190 \mu\text{M}$ and for the more active C10-benzyl (**4**), it was $0.17\text{-}16.7 \mu\text{M}$. The variation in release rates over a 10-fold concentration range permitted calculation of stoichiometry. In both cases (**4** and **8**), the Hill analysis reported a pore stoichiometry of ~ 2 . In addition, dextran blocking⁴³ of the pore sizes in both cases suggested a value near 8 Å. Data are shown in Figure 5.

The heptapeptide C-terminal ester group

The original design for a chloride-selective channel envisioned a long chain hydrocarbon anchor, a connector unit that mimicked the phospholipid's midpolar regime, and a heptapeptide. The structure of the heptapeptide was suggested by conserved sequences in the CIC family of proteins. The first compound to be prepared was terminated by a benzyl residue, primarily to protect the ionizable carboxyl group. The ester residue was varied in order to determine whether or not it had an effect on ion transport efficacy. Heptapeptides having ethyl (**9**), 2-propyl (**10**), *n*-heptyl (**11**), cyclohexylmethyl (**12**), *n*-decyl (**13**), and *n*-octadecyl (**14**) were prepared in addition to the benzyl ester (**8**) already in hand.

The graph in Figure 6 plots the fractional chloride release for C18-ester derivatives **8-14**. Surprisingly, the *n*-heptyl ester engenders the greatest chloride release. The remaining compounds fall into two groups. The cyclohexylmethyl (**12**) and *n*-decyl (**13**) esters show nearly identical chloride release behavior. The remaining compounds, the ethyl (**9**), 2-propyl (**10**), *n*-octadecyl (**14**) and benzyl esters (**8**), clearly show chloride release but it is modest at best. Our initial demonstration of chloride channel activity was with C18-benzyl ester **8**, which is among the least active compounds we have explored.

There are three surprises in these data. First, the *n*-heptyl ester (**11**) is by far the most active transporter of chloride. In terms of structure, polarity, or hydrophobicity, it seems to be in the middle of this family rather than at either extreme. The *n*-octadecyl ester constitutes the chain length and hydrophobic extreme and its low activity is the second surprise. Third, we anticipated that the cyclohexylmethyl (**12**) and benzyl (**8**) esters, being similar in size, shape, rigidity, and hydrophobicity, would be much more similar than they are. The cyclohexylmethyl ester is significantly more active than is benzyl, its isostere. It is less active than heptyl and more active than benzyl, although all three compounds have the same number of carbon atoms.

In an attempt to confirm that *n*-heptyl ester **11** did not constitute an anomaly, we undertook two different experimental studies. First, we studied the concentration dependence of its chloride release. In addition, we examined the release of carboxyfluorescein mediated by C18-heptyl ester (**11**). The release of chloride ion was assayed over a concentration range of 34–134 μM or about a fourfold change in concentration. Carboxyfluorescein was studied over a 14-fold range from 1.95–27.8 μM . The data are shown in Figure 7.

The two graphs shown in the upper and lower panels of Figure 7 demonstrate the concentration dependent release of Cl^- and CF ions, respectively. In both cases, the release of ions increases with the concentration of **11**. The experiments are not directly comparable, however. Indeed, this is a concentration-dependent study. In the 65 μM concentration case, the weight ratio of lipid to ionophore is 2.6:1 in the Cl^- release experiments and 1:20 in the fluorescence experiments. Further, the concentrations of **11** differ significantly owing to the higher concentration required for electrochemical detection compared to the fluorescence method.

C-Terminal secondary and tertiary amides as secondary anchors

Five amide compounds were examined in this part of the study. In all cases, the *N*-terminal anchors were twin octadecyl chains: **15–19**. The results of the ester studies suggested that the shortest *C*-terminal chains were likely to be inactive. Further, it appeared that a *C*-terminal residue of “intermediate” length might lead to the highest activity. A variable that is difficult to address is the importance of 2° vs. 3° amides at the *C*-terminus. Binding and transport studies conducted with lariat ether carriers having sidearms terminated by esters, 1°- or 2°-amides showed significant differences, especially between the two classes of amides.⁴⁴ We thus prepared two, 2° *C*-terminal amides: C18-decylamide (**16**) and C18-octadecylamide (**18**). We prepared three 3°, *C*-terminal amides and C18-diheptylamide (**15**) C18-didecylamide (**17**), and C18-dioctadecylamide (**19**). These five compounds were prepared by coupling the *C*-terminal acid, 18₂-[DGA]-GGGPGGG-OH, with diheptylamine (\rightarrow **15**), decylamine (\rightarrow **16**), didecylamine (\rightarrow **17**), octadecylamine (\rightarrow **18**), and dioctadecylamine (\rightarrow **19**). Standard conditions (EDCI, HOBT, CH_2Cl_2) were used and yields were 32–42% for the final products. The amides were typically white solids with melting points in the 100–200 °C range.

Release of chloride ion from liposomes was assayed with a chloride-selective electrode as described above for the esters. Data are shown in Figure 8 for **15–19**. The top curve represents chloride ion release from vesicles by C18-didecylamide, **17**. It is by far, the most active of the five compounds tested. The remaining four compounds are less active but appear to fall into two “groups” of two each. By far, the lowest Cl^- transport activity is observed for the compounds having octadecyl *C*-terminal groups (**18**, **19**), whether one or two chains are present. More active, but less active than **17**, are the 2°-decyl (**16**) and 3° diheptyl (**15**) heptapeptides.

The data set for the amides is less extensive than for the esters. Nevertheless, the C7 and C10 amides (**15–17**) proved to be much more active than the 2° or 3° C18 amides (**18**, **19**). A similar trend was observed for the esters, C18-decyl (**13**) being more active than C18-octadecyl (**14**). Of course the highest activity in the ester case was observed for the heptyl ester (**11**), with the cyclohexylmethyl ester (**12**) about as active as decyl (**13**). The C18-diheptylamide did not exhibit peak activity in the amide series, but it is clear that shorter chain lengths are favored at the *C*-terminal end of the peptide when the *N*-terminal chains are octadecyl.

General observations about the structural requirements for function

The membrane-anchored heptapeptides were designed to incorporate three structural features. The membrane anchor comprises the twin-hydrocarbon tails that were designed to mimic the fatty acyl chains of phospholipids. The midpolar regime of phospholipids is mimicked in this

design by the diglycolic acid residue, which places carbonyl groups in a position similar to that occupied by the glyceryl ester carbonyl groups. The heptapeptide was designed to serve the combined purpose of amphiphilic headgroup and selectivity filter. The C-terminal ester was incorporated to prevent the carboxyl from ionizing and potentially controlling the selectivity of the ionophore. It now seems clear that while the C-terminal ester group prevents ionization, it also serves as a “secondary” anchor system when two octadecyl chains are present at the molecule’s N-terminus.

All of the evidence accumulated to date is in concert with channel formation by dimerization of heptapeptides such as **8**. The pore size of such a dimer should be 7-8 Å. Both an examination of molecular models and dextran sizing experiments comport with this. Molecular models further suggest that the two heptapeptides “fit” together better when organized more or less as mirror images (see Figure 9) but this does not constitute evidence. We believe that the octadecyl chains play the dominant organizational role within the bilayer to form the pore. The octadecyl chains are long enough to span only one bilayer. This suggests that the known reorganization of lipid headgroups in the adjacent leaflet occurs to complete formation of the pore.⁴⁵

The ionophoretic activity data reported in this paper suggest that the C-terminal residue in $(C_{18})_2NCOCH_2OCH_2CON-GGGPGGG-OR$, $-NHR$, or $-NR^1R^2$ plays a “secondary” anchoring role. Whether the C-terminal residue is ester or amide, the greatest transport function is achieved when the N-terminal bis(octadecyl)amine derivatives possess an intermediate chain length at its C-terminus. We speculate that shorter chains do not sufficiently anchor the heptapeptide and that longer chains interfere with the dimer organization of the structure illustrated in Figure 9. Studies are currently underway to covalently link heptapeptides to assess the validity of this postulate.

Conclusions

We presented above details of the design and preparation of a novel family of membrane-active heptapeptides. The ability of these compounds to transport anions (chloride or carboxyfluorescein) through the phospholipid bilayers of synthetic liposomes was studied. Transport was found to depend on both the C- and N-terminal “anchor” chains. When a benzyl group was present at the C-terminus, anion transport increased as N-terminal chain length decreased from C_{18} to C_8 and then declined. When the N-terminal chain was bis(octadecyl), anion transport was most effective when the C-terminal “secondary anchor” was intermediate in length. Although not all C-terminal chain lengths were examined, peak activity was observed when the ester residue was *n*-heptyl (compound **11**) and when the amide residue was bis(decyl) (compound **17**). These differences cannot be attributed to hydrophilic/hydrophobic balance. We surmise that the presence of four long anchor chains prevents the dimer organization shown schematically in Figure 9. Additional studies are underway to probe this issue.

Acknowledgement

We thank the NIH for support of this work through GM 63190 and for a Chemistry-Biology Interface training grant that supported MEW.

Appendix

Appendix

Experimental section

General

^1H -NMR were recorded at 300 MHz in CDCl_3 (^{13}C -NMR at 75 MHz) and are reported in ppm (δ) downfield from internal $(\text{CH}_3)_4\text{Si}$ unless otherwise indicated. Infrared spectra were calibrated against the 1601 cm^{-1} band of polystyrene. Optical rotations were measured on a Perkin-Elmer Model 241 Polarimeter in a glass microcell (100 mm path length, 1 mL volume) with a Na gas discharge lamp as the light source. Melting points were determined on a Thomas Hoover apparatus in open capillaries and are uncorrected. Thin layer chromatographic (TLC) analyses were performed on aluminum oxide 60 F-254 neutral (Type E) with a 0.2 mm layer thickness or on silica gel 60 F-254 having a 0.2 mm layer thickness. Preparative chromatography columns were packed with activated aluminum oxide (MCB 80-325 mesh, chromatographic grade, AX 611) or with Kieselgel 60 (70-230 mesh).

All reactions were conducted under dry N_2 unless otherwise stated. All reagents were the best (non-LC) grade commercially available and were distilled, recrystallized, or used without further purification, as appropriate. Molecular distillation temperatures refer to the oven temperature of a Kugelrohr apparatus. Combustion analyses were performed by Atlantic Microlab, Inc., Atlanta, GA, and are reported as percents. Where water is factored into the analytical data, spectral evidence is presented for its presence.

General procedure 1—A solution of di-*n*-alkylamine (1.0 equiv) and diglycolic anhydride (1.1 equiv) was refluxed in THF (15 mL/g) for 48 h. The solvent was evaporated and the crude product was dissolved in CHCl_3 , washed with 10% aq HCl, and the organic layer was evaporated to dryness. The residue was recrystallized from diethyl ether to give $\text{Alk}_2\text{-[DGA]OH}$.

General procedure 2—To a $0\text{ }^\circ\text{C}$ solution of R_1COOH (1.0 equiv) in CH_2Cl_2 (30 mL/g) were added 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDCI, 1.1 equiv), 1-hydroxybenzotriazole (HOBT, 1.1 equiv), $\text{H}_2\text{N-R}_2$ tosylate or hydrochloride (1.0 equiv) and Et_3N (2 equiv). After stirring at room temperature (rt) for 48 h, the reaction was washed with 5% aq citric acid (20 mL), 5% aq NaHCO_3 (20 mL), and H_2O (20 mL). The organic phase was dried (MgSO_4), evaporated, and the residue was crystallized or chromatographed over silica gel to give R_1CONHR_2 .

General procedure 3— RCOOCH_2Ph (1.0 equiv) in EtOH (30 mL/g), 10% Pd/C (0.1 g/g of RCOOCH_2Ph) was shaken under 60 psi H_2 pressure for 3 h in a Parr apparatus. Filtration of the hot mixture through a celite pad and evaporation of the solvent gave a product that was used in the next step without further purification.

General procedure 4—Boc-protected peptide (1 equiv) was dissolved in dioxane (2 mL/g) and cooled to $0\text{ }^\circ\text{C}$. A 4N HCl solution in dioxane (4 mL/g) was added and the reaction stirred for 1.5 hours at $0\text{ }^\circ\text{C}$. The solvent was evaporated and the residue was dried at the high vacuum pump. The product was then immediately used in the next step with no further purification.

[CH₃(CH₂)₂]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, “C3-benzyl,” 1

Dipropylcarbamoylmethoxyacetic acid (3₂-[DGA]-OH)

General procedure 1. Quantities used: di-*n*-propylamine (2.0 g, 19.8 mmol) and diglycolic anhydride (2.5 g, 21.7 mmol). Product: white solid (3.2 g, 75%), mp 55-6 °C. ¹H-NMR: 0.91 (6H, m, CH₃), 1.59 (4H, m, CH₃CH₂CH₂N), 3.07 (2H, t, *J* = 7.8 Hz, CH₃CH₂CH₂N), 3.23 (2H, t, *J* = 7.8 Hz, CH₃CH₂CH₂N), 4.20 (2H, s, COCH₂O), 4.40 (2H, s, COCH₂O). ¹³C-NMR: 11.1, 11.2, 20.6, 21.7, 48.4, 71.2, 73.0, 170.8, 171.8.

3₂-[DGA]-GGG-OCH₂Ph

General procedure 2. Quantities used: 3₂-[DGA] OH (0.5 g, 2.3 mmol) and H₂N-GGG-OCH₂Ph tosylate (1.0 g, 2.3 mmol). Crude product chromatographed over silica gel (eluant CHCl₃:CH₃OH 97:3 v/v) to give 3₂-[DGA]-GGG-OCH₂Ph (0.87 g, 79%) as a light oil. ¹H-NMR: 0.89 (6H, m, CH₃), 1.55 (4H, m, CH₃CH₂CH₂N), 3.04 (2H, t, *J* = 7.5 Hz, CH₃CH₂CH₂N), 3.23 (2H, t, *J* = 7.5 Hz, CH₃CH₂CH₂N), 3.98-4.06 (6H, m, Gly CH₂), 4.09 (2H, s, COCH₂O), 4.33 (2H, s, COCH₂O), 5.14 (2H, s, PhCH₂O), 7.04 (1H, t, *J* = 5.7 Hz, NH), 7.32 (5H, m, Ar-H), 7.95 (1H, t, *J* = 5.7 Hz, Gly NH), 8.22 (1H, t, *J* = 5.7 Hz, Gly NH). ¹³C-NMR: 11.2, 11.3, 20.7, 21.9, 41.1, 43.1, 48.0, 48.4, 67.0, 69.8, 72.0, 128.2, 128.4, 128.6, 135.3, 168.7, 169.5, 169.55, 169.9, 171.5. IR (KBr): cm⁻¹ 1748 (COOR), 1652 (CO-N).

3₂-[DGA]-GGG-OH

General procedure 3. Quantities used: 3₂-[DGA]-GGG-OCH₂Ph (0.82 g, 1.7 mmol). Product: white solid (0.66 g, 100%), mp 177-8 °C, that was used in the next step without purification.

3₂-[DGA]-GGGPGGG-OCH₂Ph

General procedure 2. Quantities used: 3₂-[DGA]-GGG-OH (0.3 g, 0.8 mmol) and PGGG-OCH₂Ph-HCl (0.32 g, 0.8 mmol). Crude product recrystallized from acetone to leave a white solid (0.42 g, 74%), mp 111-2 °C. ¹H-NMR: 0.86 (6H, m, CH₃), 1.51 (4H, m, CH₃CH₂CH₂N), 1.85-2.20 (4H, m, Pro NCH₂CH₂CH₂), 2.12 (H₂O), 3.03 (2H, t, *J* = 7.5 Hz, CH₃CH₂CH₂N), 3.22 (2H, t, *J* = 7.5 Hz, CH₃CH₂CH₂N), 3.40-3.45 (1H, m, Pro NCH₂CH₂CH₂), 3.55-4.07 (13H, m, Pro NCH₂CH₂CH₂, Gly CH₂), 4.11 (2H, s, COCH₂O), 4.27 (2H, s, COCH₂O), 4.32 (1H, bs, Pro CH), 5.11 (2H, d, *J* = 5.1 Hz, PhCH₂O), 7.32 (5H, s, Ar-H), 7.54 (2H, m, Gly NH), 7.93 (2H, bt, Gly NH), 8.24 (2H, m, Gly NH). ¹³C-NMR: 11.1, 11.3, 20.7, 21.9, 25.0, 29.0, 41.2, 41.7, 42.6, 42.8, 43.4, 46.7, 47.7, 48.3, 61.1, 67.0, 69.4, 71.2, 128.1, 128.3, 128.5, 135.3, 168.5, 170.0, 170.1, 170.2, 170.7, 170.9, 173.5. Anal. Calcd. for C₃₄H₅₀N₈O₁₁·1.5H₂O: C 52.77, H 6.90, N 14.48. Found: C 52.86, H 7.05, N 14.12.

[CH₃(CH₂)₅]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, “C6-benzyl,” 2

Dihexylcarbamoylmethoxyacetic acid (6₂-[DGA]-OH)

General procedure 1. Quantities used: di-*n*-hexylamine (2.1 mL, 9.5 mmol) and diglycolic anhydride (1.00 g, 8.6 mmol). Product: pale yellow oil (2.60 g, 81%). ¹H-NMR: 0.88 (6H, m, CH₃), 1.28 (12H, m, NCH₂CH₂(CH₂)₃CH₃), 1.54 (4H, m, NCH₂CH₂(CH₂)₃CH₃), 3.07 (2H, t, *J* = 7.8 Hz, NCH₂), 3.34 (2H, t, *J* = 7.5 Hz, NCH₂), 4.20 (2H, s, COCH₂O), 4.38 (2H, s, COCH₂O). ¹³C-NMR: 13.8, 13.9, 22.4, 26.3, 26.4, 27.2, 28.4, 31.3, 31.4, 46.7, 46.8, 71.1, 72.9, 170.7, 172.1.

6₂-[DGA]-GGG-OCH₂Ph

General procedure 2. Quantities used: 6₂-[DGA] (0.50 g, 1.7 mmol) and GGG-OCH₂Ph tosylate (0.75 g, 1.7 mmol). Crude product was chromatographed over silica gel (eluant CHCl₃:CH₃OH 95:5) to give 6₂-[DGA]-GGG-OCH₂Ph (0.86 g, 92%) as a light oil. ¹H-NMR: 0.86 (6H, m, CH₃), 1.24 (12H, m, NCH₂CH₂(CH₂)₃CH₃), 1.47 (4H, m, NCH₂CH₂(CH₂)₃CH₃), 3.02 (2H, t, *J* = 7.5 Hz, NCH₂), 3.22 (2H, t, *J* = 7.8 Hz, NCH₂), 3.93-4.00 (6H, m, Gly CH₂), 4.06 (2H, s, COCH₂O), 4.26 (2H, s, COCH₂O), 5.09 (2H, s, OCH₂Ph), 7.30 (6H, m, NH, ArH), 7.92 (1H, t, *J* = 6.0 Hz, NH), 8.22 (1H, t, *J* = 6.0 Hz, NH). ¹³C-NMR: 13.96, 14.0, 22.5, 26.5, 26.7, 27.5, 28.8, 31.4, 31.5, 41.2, 43.0, 46.3, 46.8, 67.0, 69.7, 71.8, 128.4, 128.6, 128.8, 135.5, 168.7, 169.9, 170.0, 170.2, 171.5.

6₂-[DGA]-GGG-OH

General procedure 3. Quantities used: 6₂-[DGA]-GGG-OCH₂Ph (0.58 g, 1.0 mmol). Product: white solid (0.38 g, 77%), mp 121-123 °C. ¹H-NMR: 0.88 (6H, m, CH₃), 1.25 (12H, m, NCH₂CH₂(CH₂)₃CH₃), 1.49 (4H, m, NCH₂CH₂(CH₂)₃CH₃), 3.05 (2H, t, *J* = 7.8 Hz, NCH₂), 3.24 (2H, t, *J* = 7.8 Hz, NCH₂), 3.96-4.18 (8H, m, Gly CH₂, COCH₂O), 4.31 (2H, s, COCH₂O), 7.09 (1H, bt, NH), 7.91 (1H, t, *J* = 5.7 Hz, NH), 8.25 (1H, t, *J* = 6.3 Hz, NH). ¹³C-NMR: 13.9, 14.1, 22.5, 26.5, 26.6, 27.5, 28.7, 31.4, 31.5, 41.1, 42.9, 46.3, 46.8, 61.3, 69.7, 71.8, 168.7, 169.8, 170.1, 170.2, 171.5.

6₂-[DGA]-GGGPGGG-OCH₂Ph

General procedure 2. Quantities used: 6₂-[DGA]-GGG-OH (0.11 g, 0.2 mmol) and PGGG-OCH₂Ph-HCl (0.10 g, 0.2 mmol). Crude product was chromatographed over silica gel (eluant CHCl₃:CH₃OH 9:1) to give a white solid (0.15 g, 78%), mp 129-30 °C. ¹H-NMR: 0.87 (6H, m, CH₃), 1.26 (12H, m, NCH₂CH₂(CH₂)₃CH₃), 1.48 (4H, m, NCH₂CH₂(CH₂)₃CH₃), 1.85-2.2 (4H, m, Pro NCH₂CH₂CH₂), 3.06 (2H, t, *J* = 7.8 Hz, NCH₂), 3.26 (2H, t, *J* = 7.5 Hz, NCH₂), 3.40-3.58 (2H, m, Pro NCH₂CH₂CH₂), 3.7-4.16 (14 H, m, Gly CH₂, COCH₂O), 4.27 (2H, s, COCH₂O), 4.33 (1H, m, Pro CH), 5.13 (2H, dd, OCH₂Ph), 7.34 (5H, m, ArH), 7.48 (2H, m, NH), 7.90 (2H, m, NH), 8.02 (1H, t, *J* = 6.0 Hz, NH), 8.32 (1H, t, *J* = 6.0 Hz, NH). ¹³C-NMR: 14.18, 14.23, 22.7, 25.4, 26.7, 26.9, 27.7, 29.0, 29.2, 31.6, 31.7, 41.5, 42.0, 43.0, 43.2, 43.7, 46.1, 46.5, 47.1, 61.5, 67.3, 69.7, 71.7, 128.5, 128.6, 128.8, 135.6, 168.6, 168.9, 170.2, 170.4, 170.5, 171.0, 171.3, 173.7. Anal. Calcd. for C₄₀H₆₂N₈O₁₁·0.5H₂O: C 57.19, H 7.56, N 13.33. Found: C 56.91, H 7.71, N 13.12.

[CH₃(CH₂)₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, "C8-benzyl," 3**Diethylcarbamoylmethoxyacetic acid (8₂-[DGA]-OH)**

General procedure 1. Quantities used: di-*n*-octylamine (2.0 g, 8.3 mmol) and diglycolic anhydride (1.0 g, 9.1 mmol). Product: white solid (2.1 g, 73%), mp 45-6 °C. ¹H-NMR: 0.86 (6H, m, CH₃), 1.26 (20H, m, CH₃(CH₂)₅CH₂CH₂N), 1.53 (4H, m, CH₃(CH₂)₅CH₂CH₂N), 3.07 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₅CH₂CH₂N), 3.32 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₅CH₂CH₂N), 4.19 (2H, s, COCH₂O), 4.37 (2H, s, COCH₂O). ¹³C-NMR: 14.0, 22.5, 25.8, 26.7, 26.9, 27.3, 28.5, 29.0, 29.1, 29.2, 31.6, 31.7, 46.7, 46.8, 71.1, 72.8, 170.5, 171.8.

8₂-[DGA]-GGG-OCH₂Ph

General procedure 2. Quantities used: 8₂-[DGA] (0.5 g, 1.4 mmol) and GGG-OCH₂Ph tosylate (0.63 g, 1.4 mmol). Crude product was chromatographed over silica gel (eluant CHCl₃:CH₃OH 98:2) to give 8₂-[DGA]-GGG-OCH₂Ph (0.76 g, 88%) as a colorless oil. ¹H-NMR: 0.86 (6H, m, CH₃), 1.25 (20H, m, CH₃(CH₂)₅CH₂CH₂N), 1.50 (4H, m,

$\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 3.05 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 3.25 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 3.97-4.05 (6H, m, Gly CH_2), 4.10 (2H, s, COCH_2O), 4.31 (2H, s, COCH_2O), 5.14 (2H, s, PhCH_2O), 7.09 (1H, t, $J = 5.1$ Hz, NH), 7.34 (5H, m, Ar-H), 7.89 (1H, t, $J = 6.3$ Hz, Gly NH), 8.27 (1H, t, $J = 6.0$ Hz, Gly NH). ^{13}C -NMR: 14.0, 22.56, 22.59, 26.8, 27.0, 27.5, 28.8, 29.1, 29.2, 29.3, 31.7, 31.8, 41.1, 43.1, 46.4, 46.8, 67.0, 71.9, 128.2, 128.4, 128.6, 135.3, 168.5, 169.5, 169.6, 169.9, 171.4.

8₂-[DGA]-GGG-OH

General procedure 3. Quantities used: 8₂-[DGA]-GGG-OCH₂Ph (1.0 g, 1.62 mmol). Product: white solid (0.85 g, 100%), mp 125-7 °C. This product was used directly in the subsequent reaction.

8₂-[DGA]-GGGPGGG-OCH₂Ph

General procedure 2. Quantities used: 8₂-[DGA]-GGG-OH (0.3 g, 0.6 mmol) and PGGG-OCH₂Ph-HCl (0.23 g, 0.6 mmol). Crude product crystallized from CH₃OH to leave a white solid (0.25 g, 50%), mp 116-7 °C. ^1H -NMR: 0.85 (6H, m, CH₃), 1.24 (20H, m, $\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 1.47 (4H, m, $\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 1.85-2.20 (4H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.03 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 3.24 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_5\text{CH}_2\text{CH}_2\text{N}$), 3.40-3.45 (1H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.75-4.07 (13H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$, Gly CH_2), 4.08 (2H, s, COCH_2O), 4.25 (2H, s, COCH_2O), 4.33 (1H, bs, Pro CH), 5.11 (2H, d, $J = 5.1$ Hz, PhCH_2O), 7.32 (5H, s, Ar-H), 7.58 (2H, bt, Gly NH), 7.93 (1H, bt, Gly NH), 7.95 (1H, bt, Gly NH), 8.26 (1H, m, Gly NH), 8.31 (1H, m, Gly NH). ^{13}C -NMR: 14.2, 22.7, 25.3, 27.0, 27.2, 27.7, 29.0, 29.2, 29.3, 29.4, 29.5, 31.88, 31.94, 41.4, 42.0, 42.9, 43.0, 43.6, 46.4, 47.0, 61.3, 67.2, 69.2, 69.5, 71.4, 128.3, 128.5, 128.7, 135.6, 168.5, 168.9, 170.31, 170.38, 170.40, 170.6, 171.0, 171.1, 173.8. Anal. Calcd. for $\text{C}_{44}\text{H}_{70}\text{N}_8\text{O}_{11} \cdot 0.5\text{H}_2\text{O}$: C 58.98, H 7.99, N 12.50. Found: C 59.04, H 7.95, N 12.63.

[CH₃(CH₂)₉]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, "C10-benzyl," 4

This compound was prepared as previously described.^{30d}

[CH₃(CH₂)₁₁]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, "C12-benzyl," 5

Didodecylcarbamoylmethoxyacetic acid (12₂-[DGA]-OH)

General procedure 1. Quantities used: di-*n*-dodecylamine (1.0 g, 2.8 mmol) and diglycolic anhydride (0.3 g, 2.6 mmol). Product: white solid (1.20 g, 90%), mp 59-60 °C. ^1H -NMR: 0.88 (6H, m, CH₃), 1.26 (36H, m, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 1.54 (4H, m, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 3.07 (2H, t, $J = 7.8$ Hz, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 3.34 (2H, t, $J = 7.2$ Hz, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 4.20 (2H, s, COCH_2O), 4.38 (2H, s, COCH_2O). ^{13}C -NMR: 14.1, 22.6, 26.8, 26.9, 27.4, 28.6, 29.2, 29.3, 29.5, 31.9, 46.8, 71.2, 73.1, 170.3, 170.6.

12₂-[DGA]-GGG-OCH₂Ph

General procedure 2. Quantities used: 12₂-[DGA]-OH (0.17 g, 0.4 mmol) and TsOH·H₂N-GGG-OCH₂Ph (0.16 g, 0.4 mmol). Crude product was chromatographed (silica gel, eluant CHCl₃:CH₃OH 95:5) to give 12₂-[DGA]-GGG-OCH₂Ph (0.15 g, 58%) as a colorless oil. ^1H -NMR: 0.88 (6H, m, CH₃), 1.25 (36H, m, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 1.51 (4H, m, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 3.05 (2H, t, $J = 7.8$ Hz, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 3.26 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CH}_2\text{N}$), 3.98-4.06 (6H, m, Gly CH_2), 4.10 (2H, s, COCH_2O), 4.31 (2H, s, COCH_2O), 5.14 (2H, s, PhCH_2O), 7.18 (1H, bs, NH), 7.34 (5H, m, Ar-H), 7.94 (1H, t, $J = 5.7$ Hz, NH), 8.27 (1H, t, $J = 6.0$ Hz, NH). ^{13}C -NMR: 14.0, 22.5, 26.7, 26.9, 27.4, 28.6, 29.2, 29.3,

29.4, 29.5, 31.8, 41.0, 43.0, 46.3, 46.7, 66.9, 69.6, 71.8, 128.3, 128.4, 128.6, 135.3, 168.6, 169.7, 169.8, 170.1, 171.6.

12₂-[DGA]-GGG-OH

General procedure 3. Quantities used: 12₂-[DGA]-GGG-OCH₂Ph (0.15 g, 0.2 mmol). Product: white solid (0.116 g, 100%), mp 122-3°C. ¹H-NMR (CD₃OD): 0.95 (6H, t, *J* = 6.6 Hz, CH₃), 1.23 (36H, m, CH₃(CH₂)₉CH₂CH₂N), 1.45 (4H, m, CH₃(CH₂)₉CH₂CH₂N), 3.11 (2H, t, *J* = 7.2 Hz, CH₃(CH₂)₉CH₂CH₂N), 3.19 (2H, t, *J* = 7.2 Hz, CH₃(CH₂)₉CH₂CH₂N), 3.72-3.80 (6H, m, Gly CH₂), 3.97 (2H, s, COCH₂O), 4.28 (2H, s, COCH₂O), 8.17 (2H, m, NH), 8.25 (1H, t, *J* = 6.0 Hz, NH). ¹³C-NMR (CD₃OD): 13.9, 22.1, 26.2, 26.4, 27.1, 28.3, 28.7, 29.0, 31.3, 41.6, 41.8, 45.1, 46.1, 68.8, 70.3, 168.3, 169.2, 169.4, 169.7, 171.4.

12₂-[DGA]-GGGPGGG-OCH₂Ph

General procedure 2. Quantities used: 12₂-[DGA]-GGG-OH (0.10 g, 0.2 mmol) and PGGG-OCH₂Ph-HCl (0.075 g, 0.2 mmol). Crude product was chromatographed (silica gel, CHCl₃:CH₃OH 95:5) and crystallized from CH₃OH to leave a white solid (0.093 g, 60%), mp 111-2 °C. ¹H-NMR: 0.87 (6H, t, *J* = 6.3 Hz, CH₃), 1.25 (36H, m, CH₃(CH₂)₉CH₂CH₂N), 1.48 (4H, m, CH₃(CH₂)₉CH₂CH₂N), 1.85-2.20 (4H, m, Pro NCH₂CH₂CH₂), 3.08 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₉CH₂CH₂N), 3.24 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₉CH₂CH₂N), 3.48 (1H, m, Pro NCH₂CH₂CH₂), 3.59 (1H, m, Pro NCH₂CH₂CH₂), 3.77-4.17 (14H, Gly CH₂, COCH₂O), 4.28 (2H, s, COCH₂O), 4.34 (1H, bs, Pro CH), 5.14 (2H, d, *J* = 3.9 Hz, PhCH₂O), 7.34 (5H, s, Ar-H), 7.46 (2H, m, Gly NH), 7.87 (3H, m, Gly NH), 8.37 (1H, bs, Gly NH). ¹³C-NMR: 14.2, 22.7, 25.3, 27.0, 27.2, 27.7, 29.0, 29.2, 29.3, 29.4, 29.5, 31.88, 31.94, 41.4, 42.0, 42.9, 43.0, 43.6, 46.4, 47.0, 61.3, 67.2, 69.2, 69.5, 71.4, 128.3, 128.5, 128.7, 135.6, 168.5, 168.9, 170.31, 170.38, 170.40, 170.6, 171.0, 171.1, 173.8. Anal. Calcd. for C₅₂H₈₆N₈O₁₁·H₂O: C 61.39, H 8.72, N 11.01. Found: C 61.39, H 8.67, N 10.93.

[CH₃(CH₁₃)₂]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, "C14-benzyl," 6

Di-*n*-tetradecylamine

A solution of tetradecylamine (5.0 g, 21.5 mmol), DMAP (0.4 g, 3.3 mmol) and NEt₃ (5.0 mL) in toluene (60 mL) was cooled to 0 °C and a solution of myristoyl chloride (5.5 g, 21.6 mmol) in toluene (50 mL) was added dropwise. The reaction was stirred at rt (2 da), the solvent was removed, and the residue crystallized twice from ethanol and dried *in vacuo* to constant weight. This product (8.4 g, 19.8 mmol) was dissolved in anhydrous THF and a suspension of LiAlH₄ (1.5 g, 39.5 mmol) in THF was carefully added. The reaction was heated (reflux, 18 h), then cooled (rt) and poured into 10% aq Na₂SO₄ (300 mL), CHCl₃ (300 mL) was added, and the mixture was stirred and filtered. The solid was washed with chloroform, the filtrates were combined, and the organic phase was washed with brine and evaporated. The residue was crystallized from EtOH to give HN((CH₂)₁₃CH₃)₂ (7.35 g, 83%), mp 59-60 °C. ¹H-NMR: 0.87 (6H, t, *J* = 6.6 Hz, CH₃), 1.25 (44H, m, CH₃(CH₂)₁₁CH₂CH₂N), 1.47 (4H, m, CH₃(CH₂)₁₁CH₂CH₂N), 2.57 (4H, t, *J* = 7.2 Hz, CH₃(CH₂)₁₁CH₂CH₂N). ¹³C-NMR: 14.3, 22.9, 27.6, 29.6, 29.8, 29.9, 30.4, 32.1, 50.4.

Ditetradecylcarbamoylmethoxyacetic acid (14₂-[DGA]-OH)

General procedure 1. Quantities used: di-*n*-tetradecylamine (7.00 g, 17.1 mmol) and diglycolic anhydride (2.0 g, 17.2 mmol). Product: white solid (7.12 g, 79%), mp 72-4 °C. ¹H-NMR: 0.87 (6H, t, *J* = 7.2 Hz, CH₃), 1.25 (44H, m, CH₃(CH₂)₁₁CH₂CH₂N), 1.54 (4H, m, CH₃(CH₂)₁₁CH₂CH₂N), 3.07 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₁CH₂CH₂N), 3.34 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₁₁CH₂CH₂N), 4.20 (2H, s, COCH₂O), 4.38 (2H, s, COCH₂O). ¹³C-NMR: 14.2,

22.8, 26.9, 27.1, 27.5, 28.7, 29.2, 29.4, 29.5, 29.6, 29.7, 29.8, 32.0, 46.9, 47.0, 71.1, 72.8, 170.6, 172.1.

14₂-[DGA]-GGG-OCH₂Ph

General procedure 2. Quantities used: 14₂-[DGA] (0.98 g, 1.9 mmol) and GGG-OCH₂Ph tosylate (0.84 g, 1.9 mmol). Crude product was chromatographed (silica gel, CHCl₃:CH₃OH 95:5) to give a colorless oil (1.12 g, 76%). ¹H-NMR: 0.86 (6H, t, *J* = 6.9 Hz, CH₃), 1.23 (44H, m, CH₃(CH₂)₁₁CH₂CH₂N), 1.48 (4H, m, CH₃(CH₂)₁₁CH₂CH₂N), 3.04 (2H, t, *J* = 8.1 Hz, CH₃(CH₂)₁₁CH₂CH₂N), 3.24 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₁₁CH₂CH₂N), 3.96-4.02 (6H, m, Gly CH₂), 4.08 (2H, s, COCH₂O), 4.28 (2H, s, COCH₂O), 5.12 (2H, s, PhCH₂O), 7.30 (6H, bs, NH, Ar-H), 7.92 (1H, t, *J* = 5.7 Hz, Gly NH), 8.26 (1H, t, *J* = 6.0 Hz, Gly NH). ¹³C-NMR: 14.2, 22.8, 27.0, 27.2, 27.7, 28.9, 29.5, 29.7, 29.8, 32.0, 41.3, 43.2, 46.5, 47.0, 67.1, 69.8, 71.9, 128.3, 128.5, 128.7, 135.5, 168.6, 169.7, 169.8, 170.1, 171.4.

14₂-[DGA]-GGG-OH

General procedure 3. Quantities used: 14₂-DGA-[GGG]-OCH₂Ph (1.10 g, 1.4 mmol). A white solid (0.87 g, 89 %), mp 125-7 °C. ¹H-NMR (CDCl₃-CD₃OD 9:1): 0.72 (6H, t, *J* = 6.6 Hz, CH₃), 1.13 (44H, m, CH₃(CH₂)₁₁CH₂CH₂N), 1.40 (4H, m, CH₃(CH₂)₁₁CH₂CH₂N), 2.96 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₁CH₂CH₂N), 3.16 (2H, t, *J* = 7.2 Hz, CH₃(CH₂)₁₁CH₂CH₂N), 3.80-3.83 (6H, m, Gly CH₂), 3.96 (2H, s, COCH₂O), 4.15 (2H, s, COCH₂O). ¹³C-NMR (CDCl₃:CD₃OD 9:1): 13.9, 22.6, 26.7, 26.9, 27.4, 28.7, 29.0, 29.2, 29.5, 29.6, 31.8, 40.9 (bs), 42.5, 46.3, 46.9, 68.9, 70.8, 168.5, 170.2, 171.4, 171.6.

14₂-[DGA]-GGGPGGG-OCH₂Ph

General procedure 2. Quantities used: 14₂-[DGA]-GGG-OH (0.80 g, 1.2 mmol) and PGGG-OCH₂Ph-HCl (0.55 g, 1.3 mmol). Crude product was chromatographed (silica gel, CHCl₃:CH₃OH 98:2 9:1) to give a solid, which was crystallized from CH₃OH (0.92 g, 76%), m.p 127-9 °C. ¹H-NMR: 0.85 (6H, t, *J* = 6.6 Hz, CH₃), 1.23 (44H, m, CH₃(CH₂)₁₁CH₂CH₂N), 1.46 (4H, m, CH₃(CH₂)₁₁CH₂CH₂N), 1.85-2.15 (4H, m, Pro NCH₂CH₂CH₂), 3.04 (2H, t, *J* = 6.9 Hz, CH₃CH₂(CH₂)₁₁CH₂N), 3.23 (2H, t, *J* = 7.2 Hz, CH₃CH₂(CH₂)₁₁CH₂N), 3.46 (2H, m, Pro NCH₂CH₂CH₂), 3.72-4.10 (14H, Gly CH₂, COCH₂O), 4.24 (2H, s, COCH₂O), 4.32 (1H, bs, Pro CH), 5.10 (2H, d, *J* = 6.3 Hz, PhCH₂O), 7.31 (5H, s, Ar-H), 7.55 (2H, m, Gly NH), 7.90 (2H, m, Gly NH), 8.23 (2H, bt, Gly NH). ¹³C-NMR: 14.2, 22.8, 25.2, 27.0, 27.2, 27.7, 29.0, 29.1, 29.4, 29.5, 29.6, 29.7, 32.0, 41.3, 41.9, 42.8, 43.0, 43.6, 46.4, 47.0, 61.2, 67.1, 69.5, 71.4, 128.3, 128.4, 128.7, 135.6, 168.4, 168.7, 170.19, 170.25, 170.3, 170.4, 170.9, 171.0, 173.7. Anal. Calcd. for C₅₆H₉₄N₈O₁₁·H₂O: C 62.66, H 9.01, N 10.43. Found: C 62.76, H 8.83, N 10.38.

CH₃(CH₁₅)₂]NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂C₆H₅, "C16-benzyl," 7

Di-*n*-hexadecylamine

The procedure used for di-*n*-tetradecylamine was employed using hexadecylamine and palmitoyl chloride (65%), mp 79-80 °C. ¹H-NMR: 0.87 (6H, t, *J* = 7.2 Hz, CH₃), 1.25 (52H, m, CH₃(CH₂)₁₃CH₂CH₂N), 1.48 (4H, m, CH₃(CH₂)₁₃CH₂CH₂N), 2.58 (4H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₃CH₂CH₂N). ¹³C-NMR: 14.3, 22.9, 27.6, 29.6, 29.8, 29.9, 30.3, 32.1, 50.3.

Di-*n*-hexadecylcarbamoylmethoxyacetic acid (16₂-[DGA]-OH)

General procedure 1. Quantities used: di-*n*-hexadecylamine (8.5 g, 18.4 mmol) and diglycolic anhydride (2.14 g, 17.2 mmol). The product was a white solid (8.60 g, 80%), mp 79-81 °

C. $^1\text{H-NMR}$: 0.87 (6H, t, $J = 6.3$ Hz, CH_3), 1.24 (52H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 1.53 (4H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 3.07 (2H, t, $J = 7.8$ Hz, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 3.33 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 4.19 (2H, s, COCH_2O), 4.37 (2H, s, COCH_2O). $^{13}\text{C-NMR}$: 14.3, 22.9, 27.0, 27.1, 27.6, 28.8, 29.4, 29.5, 29.6, 29.7, 29.8, 29.9, 32.1, 47.0, 71.3, 73.0, 170.7, 172.0.

16₂-[DGA]-GGG-OCH₂Ph

General procedure 2. Quantities used: 16₂-[DGA] (1.10 g, 1.9 mmol) and GGG-OCH₂Ph tosylate (0.85 g, 1.9 mmol). Crude product was chromatographed (silica gel, $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5) to give the product (1.28 g, 81%), a colorless oil. $^1\text{H-NMR}$: 0.85 (6H, t, $J = 6.9$ Hz, CH_3), 1.23 (44H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 1.48 (4H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 3.03 (2H, t, $J = 7.8$ Hz, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 3.23 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 3.94-4.01 (6H, m, Gly CH_2), 4.07 (2H, s, COCH_2O), 4.27 (2H, s, COCH_2O), 5.10 (2H, s, PhCH_2O), 7.30 (6H, bs, NH, Ar-H), 7.92 (1H, t, $J = 6.0$ Hz, NH), 8.23 (1H, t, $J = 6.0$ Hz, NH). $^{13}\text{C-NMR}$: 14.2, 22.8, 27.0, 27.1, 27.7, 28.9, 29.4, 29.5, 29.6, 29.8, 32.0, 41.2, 43.1, 46.5, 46.9, 67.0, 69.7, 71.8, 128.3, 128.4, 128.7, 135.4, 168.5, 169.7, 169.8, 170.0, 171.3.

16₂-[DGA]-GGG-OH

General procedure 3. Quantities used: 16₂-[DGA]-GGG-OCH₂Ph (1.25 g, 1.5 mmol). Product: white solid (1.0 g, 90 %), mp 188-90 °C. $^1\text{H-NMR}$ ($\text{CDCl}_3:\text{CD}_3\text{OD}$ 4:1): 0.74 (6H, t, $J = 6.9$ Hz, CH_3), 1.12 (52H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 1.41 (4H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 2.97 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 3.16 (2H, t, $J = 7.2$ Hz, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{N}$), 3.79 (2H, s, Gly CH_2), 3.80 (2H, s, Gly CH_2), 3.83 (2H, s, Gly CH_2), 3.90 (2H, s, COCH_2O), 4.16 (2H, s, COCH_2O). $^{13}\text{C-NMR}$ ($\text{CDCl}_3:\text{CD}_3\text{OD}$ 4:1): 13.9, 22.6, 26.8, 26.9, 27.4, 28.7, 29.22, 29.25, 29.4, 29.5, 29.56, 29.60, 31.8, 41.3 (bs), 42.50, 42.55, 46.3, 46.9, 68.9, 70.7, 168.5, 170.1, 170.2, 171.4, 172.3.

16₂-[DGA]-GGGPGGG-OCH₂Ph

General procedure 2. Quantities used: 16₂-[DGA]-GGG-OH (0.95 g, 1.3 mmol) and PGGG-OCH₂Ph-HCl (0.57 g, 1.4 mmol). The crude material was chromatographed (silica gel, $\text{CHCl}_3:\text{CH}_3\text{OH}$ 98:2 9:1) and crystallized from CH_3OH to give a white solid (1.0 g, 72%), mp 131-3 °C. $^1\text{H-NMR}$: 0.84 (6H, t, $J = 6.3$ Hz, CH_3), 1.22 (52H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 1.46 (4H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CH}_2\text{N}$), 1.85-2.15 (4H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.03 (2H, t, $J = 7.5$ Hz, $\text{CH}_3\text{CH}_2(\text{CH}_2)_{13}\text{CH}_2\text{N}$), 3.22 (2H, t, $J = 6.9$ Hz, $\text{CH}_3\text{CH}_2(\text{CH}_2)_{13}\text{CH}_2\text{N}$), 3.46 (2H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.71-4.10 (14H, Gly CH_2 , COCH_2O), 4.24 (2H, s, COCH_2O), 4.32 (1H, bs, Pro CH), 5.09 (2H, d, $J = 6.3$ Hz, PhCH_2O), 7.30 (5H, s, Ar-H), 7.55 (2H, m, NH), 7.90 (2H, m, NH), 8.21 (2H, bt, NH). $^{13}\text{C-NMR}$: 14.2, 22.8, 25.2, 27.0, 27.2, 27.7, 29.0, 29.1, 29.4, 29.5, 29.7, 29.8, 32.0, 41.3, 41.9, 42.8, 43.0, 43.6, 46.4, 46.9, 47.0, 61.2, 67.1, 69.6, 71.4, 128.3, 128.4, 128.7, 135.6, 168.4, 168.6, 170.21, 170.24, 170.30, 170.34, 170.8, 171.0, 173.7. Anal. Calcd. for $\text{C}_{60}\text{H}_{102}\text{N}_8\text{O}_{11}\cdot 0.5\text{H}_2\text{O}$: C 64.32, H 9.27, N 9.99. Found: C 64.50, H 9.28, N 10.00.

$[\text{CH}_3(\text{CH}_2)_{17}]_2\text{NCOCH}_2\text{OCH}_2\text{CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH}_2\text{C}_6\text{H}_5$, "C18-benzyl," 8

This compound was prepared as described in detail previously.^{31d}

18₂-[DGA]-GGGPGGG-OH

General procedure 3. Quantities used: 18₂-[DGA]-GGGPGGG-OCH₂Ph (1.0 g, 0.9 mmol). Product: white solid (0.87 g, 94%), mp 167 °C dec. $^1\text{H-NMR}$: 0.84 (6H, t, $J = 6.9$ Hz, CH_3), 1.22 (60H, m, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 1.50 (4H, bs, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 1.80-2.20 (4H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.06 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{16}\text{CH}_2\text{N}$), 3.26 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{16}\text{CH}_2\text{N}$), 3.00-4.40 (19H, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$, Gly CH_2 , COCH_2O , Pro CH), 7.50

(1H, t, $J = 6.0$ Hz, NH), 7.69 (1H, t, $J = 6.0$ Hz, NH), 7.90-8.05 (2H, m, NH), 8.32 (1H, bs, NH). $^{13}\text{C-NMR}$: 14.1, 22.7, 25.1, 26.9, 27.1, 27.6, 28.8, 29.3, 29.4, 29.6, 29.7, 31.9, 41.6, 41.9, 42.6, 42.8, 43.4, 46.4, 47.0, 61.2, 69.0, 70.9, 168.6, 168.9, 170.4, 170.8, 171.0, 171.3, 172.6, 173.7. IR (CHCl_3): cm^{-1} 3306, 3083, 2918, 2850, 1730, 1658, 1651, 1646, 1540, 1467, 1412, 1378, 1338, 1241, 1130, 1030, 909, 722.

$[\text{CH}_3(\text{CH}_2)_{17}]_2\text{NCOCH}_2\text{OCH}_2\text{CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH}_2\text{CH}_3$, "C18-ethyl," 9

TsOH-GGG-OEt

Triglycine (2.0 g, 10.6 mmol), *p*-TsOH (2.2 g, 11.6 mmol), EtOH (10 mL, 0.17 mol), and toluene (50 mL) were heated at reflux for 4 da (water removed by Dean-Stark trap) and the solvent was then evaporated. The residue was dissolved in CH_3OH and Et_2O was added until cloudy. Cooling overnight (4 °C) precipitated a white solid (3.4 g, 83%), mp 140-2 °C. $^1\text{H-NMR}$ ($\text{CDCl}_3:\text{CD}_3\text{OD}$ 9:1): 1.05 (3H, t, $J = 7.2$ Hz, CH_2CH_3), 2.18 (3H, s, Ar- CH_3), 3.65 (2H, s, Gly CH_2), 3.70 (2H, s, Gly CH_2), 3.77 (2H, s, Gly CH_2), 3.96 (2H, q, $J = 7.2$ Hz, CH_2CH_3), 6.99 (2H, d, $J = 8.1$ Hz, ArH), 7.50 (2H, d, $J = 8.1$ Hz, ArH). $^{13}\text{C-NMR}$ ($\text{CDCl}_3:\text{CD}_3\text{OD}$ 9:1): 12.7, 20.9, 40.8, 40.9, 42.5, 42.6, 61.3, 125.5, 128.8, 140.7, 141.2, 167.1, 167.2, 170.1.

Boc-PGGG-OEt

General procedure 2. Quantities used: Boc-L-Proline (0.35g, 1.6 mmol) and GGG-OEt tosylate (0.63 g, 1.6 mmol). The crude material was chromatographed (silica gel, $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5 9:1) to give the final product (0.60 g, 88%) as a colorless oil. $^1\text{H-NMR}$: 1.18 (3H, t, $J = 6.6$ Hz, CH_2CH_3), 1.35 (9H, s, C (CH_3)₃), 1.75-2.15 (4H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.40 (2H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.75-4.00 (7H, m, Gly CH_2 , Pro CH), 4.09 (2H, q, $J = 7.2$ Hz, CH_2CH_3), 7.32 (2H, bs, NH), 7.65 (2H, bs, NH), 7.92 (2H, bs, NH). $^{13}\text{C-NMR}$: 14.2, 24.7, 28.4, 29.8, 41.3, 43.0, 43.3, 47.3, 60.7, 61.3, 77.4, 80.7, 155.6, 169.7, 169.8, 170.3, 174.1

PGGG-OEt-HCl

General procedure 4. Quantities used: Boc-PGGG-OEt (0.23 g, 0.5 mmol). The product was used immediately in the subsequent reaction.

18₂-[DGA]-GGGPGGG-OEt

General procedure 2. Quantities used: 18₂-[DGA]-GGG-OH (0.43 g, 0.5 mmol) and PGGG-OEt-HCl (0.19 g, 0.5 mmol). The crude material was chromatographed (silica gel, $\text{CHCl}_3:\text{CH}_3\text{OH}$ 95:5 9:1) to give the final product (0.22 g, 38%) as a white solid, mp 127-9 °C. $^1\text{H-NMR}$: 0.84 (9H, t, $J = 6.9$ Hz, CH_3), 1.22 (60H, m, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 1.48 (4H, m, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 1.85-2.21 (4H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.05 (2H, t, $J = 7.5$ Hz, $\text{CH}_3\text{CH}_2(\text{CH}_2)_{15}\text{CH}_2\text{N}$), 3.23 (2H, t, $J = 7.2$ Hz, $\text{CH}_3\text{CH}_2(\text{CH}_2)_{15}\text{CH}_2\text{N}$), 3.53 (1H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.60 (1H, m, Pro $\text{NCH}_2\text{CH}_2\text{CH}_2$), 3.73-4.15 (16H, Gly CH_2 , COCH_2O , OCH_2CH_3), 4.26 (2H, s, COCH_2O), 4.35 (1H, m, Pro CH), 7.53 (1H, bt, NH), 7.59 (1H, bt, NH), 7.91 (2H, m, NH), 8.25 (2H, bt, NH). $^{13}\text{C-NMR}$: 14.2, 22.8, 25.3, 27.0, 27.2, 27.8, 29.0, 29.2, 29.5, 29.6, 29.7, 29.8, 32.0, 41.4, 42.0, 42.8, 43.0, 43.6, 46.4, 47.0, 61.3, 61.5, 69.5, 71.4, 168.5, 168.8, 170.3, 170.5, 170.9, 171.1, 173.7. Anal. Calcd. for $\text{C}_{59}\text{H}_{108}\text{N}_8\text{O}_{11}\cdot\text{H}_2\text{O}$: C 63.07, H 9.87, N 9.97. Found: C 63.01, H 9.79, N 10.11.

**[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₂(CH₃)₂,
“C18-isopropyl,” 10**

HCl-GGG-OCH(CH₃)₂

GGG (1.0 g, 5.3 mmol) was suspended in 2-PrOH (10 mL), cooled (5 °C), SOCl₂ (0.8 mL, 11.0 mmol) was added dropwise, and the mixture was heated under reflux (4 da). After evaporation of solvent, toluene (20 mL) was added and evaporated. The residue was dried at high vacuum and crystallized from CH₃OH:Et₂O (20 mL:40 mL) to give white crystals which were crystallized a second time to afford pure product (0.87 g, 61%), mp 185-186 °C. ¹H-NMR (CD₃OD): 1.25 (6H, d, *J* = 6.3 Hz, OCH(CH₃)₂), 3.76 (2H, s, Gly CH₂), 3.92 (2H, s, Gly CH₂), 4.00 (2H, s, Gly CH₂), 5.04 (1H, m, OCH(CH₃)₂). ¹³C-NMR (CD₃OD): 22.1, 41.7, 42.4, 43.2, 70.4, 168.0, 170.9, 171.9. IR (nujol): cm⁻¹ 3330, 3232, 2954, 2924, 2854, 1732, 1703, 1646, 1789, 1573, 1548, 1489, 1461, 1411, 1377, 1219, 1153, 1102, 1033, 961, 911, 820, 723.

Cbz-PGGG-OCH(CH₃)₂

General procedure 2. Quantities used: Cbz-L-Proline (0.48 g, 1.9 mmol), and HCl-GGG-O-CH(CH₃)₂ (0.5 g, 1.9 mmol). The crude material was chromatographed (silica gel, CH₃OH:CH₂Cl₂ 98:2 85:5) to give colorless crystals (0.74 g, 86%), mp 93-95 °C. ¹H-NMR: 1.21 (6H, d, *J* = 6.3 Hz, OCH(CH₃)₂), 1.80-2.10 (4H, m, Pro NCH₂CH₂CH₂), 3.45-3.60 (2H, m, Pro NCH₂CH₂CH₂), 3.80-4.10 (6H, Gly CH₂), 4.24 (1H, t, *J* = 6.3 Hz, Pro CH), 4.90-5.20 (3H, OCH(CH₃)₂, PhCH₂O), 7.08 (1H, t, *J* = 6.0 Hz, NH), 7.33 (5H, Ar-H), 7.44 (1H, t, *J* = 6.0 Hz, NH), 7.75 (1H, t, *J* = 6.0 Hz, NH). ¹³C-NMR: 21.7, 24.7, 29.5, 41.4, 42.9, 43.3, 47.1, 61.0, 67.5, 69.0, 127.7, 128.1, 128.5, 136.2, 156.0, 169.1, 169.5, 169.9, 173.3. IR (CHCl₃): cm⁻¹ 3312, 3066, 2981, 2938, 2882, 1744, 1669, 1541, 1420, 1376, 1359, 1210, 1108, 1031, 984, 947, 920, 772, 734, 699, 669.

PGGG-OCH(CH₃)₂

General procedure 3. Quantities used: Cbz-PGGG-OCH(CH₃)₂ (0.36 g, 0.8 mmol). Product: white solid (0.25 g, 100%), mp 144-145 °C. ¹H-NMR (CD₃OD): 1.251 (6H, d, *J* = 6.3 Hz, OCH(CH₃)₂), 1.75-2.30 (4H, m, Pro NCH₂CH₂CH₂), 3.00-3.15 (2H, m, Pro NCH₂CH₂CH₂), 3.85-3.95 (7H, Gly CH₂, and Pro CH), 5.02 (1H, m, OCH(CH₃)₂). ¹³C-NMR (CD₃OD): 22.1, 26.7, 31.7, 42.4, 43.4, 43.7, 48.0, 61.6, 70.4, 170.9, 172.2, 176.7. IR (nujol): cm⁻¹ 3177, 2922, 2855, 2726, 1740, 1647, 1542, 1461, 1377, 1304, 1206, 1170, 1028, 967, 770, 722.

18₂-[DGA]-GGGPGGG-OCH(CH₃)₂

General procedure 2. Quantities used: 18₂-[DGA]-GGG-OH (0.27 g, 0.3 mmol) and PGGG-OCH(CH₃)₂ (0.11 g, 0.3mmol). Crude product was crystallized (2 CH₃OH) to give a white solid (0.26 g, 70%), mp 129-131 °C. ¹H-NMR: 0.87 (6H, t, *J* = 6.9 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 1.20-1.30 (66H, CH₃(CH₂)₁₅CH₂CH₂N, OCH(CH₃)₂), 1.51 (2H, m, CH₃(CH₂)₁₅CH₂CH₂N), 1.95-2.25 (4H, m, Pro NCH₂CH₂CH₂), 3.08 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 3.27 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 3.75-4.40 (19H, Pro NCH₂CH₂CH₂, Gly CH₂, Pro CH, and COCH₂O), 5.01 (1H, m, OCH(CH₃)₂), 7.33 (1H, bs, NH), 7.50 (1H, bs, NH), 7.87 (3H, bs, NH), 8.34 (1H, bs, NH). ¹³C-NMR: 14.1, 21.8, 22.7, 25.2, 26.9, 27.1, 27.6, 28.9, 29.0, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9, 41.5, 42.0, 43.0, 43.5, 46.3, 47.0, 61.3, 69.2, 69.6, 71.6, 168.4, 168.8, 169.5, 170.0, 170.1, 170.3, 170.6, 171.2, 173.2. IR (CHCl₃): cm⁻¹ 3308, 2920, 2851, 1744, 1652, 1540, 1467, 1376, 1338, 1209, 1129, 1109, 1031, 722. Anal. Calcd. for C₆₀H₁₁₀N₈O₁₁·H₂O: C 63.35, H 9.92, N 9.85. Found: C 63.40, H 9.92, N 9.52.

**[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-O(CH₂)₆CH₃,
“C18-heptyl,” 11**

TsOH-GGG-OC₇H₁₅

GGG (2.0 g, 10.6 mmol) and *p*-TsOH·H₂O (2.2 g, 11.6 mmol) were added to 1-heptanol (12 g, 103.3 mmol) and toluene (40 mL). The mixture was heated to reflux and water was removed azeotropically (Dean-Stark trap, 3 h). The mixture was cooled (rt), evaporated, and crystallized from CH₃OH:Et₂O (20 mL:60 mL) to give 4.32 g (89%) of a white solid, mp 149-150 °C. ¹H-NMR (CD₃OD): 0.91 (3H, t, *J* = 7.2 Hz, CH₃(CH₂)₄CH₂CH₂O), 1.32 (8H, m, CH₃(CH₂)₄CH₂CH₂O), 1.64 (2H, bs, CH₃(CH₂)₄CH₂CH₂O), 2.37 (3H, s, Ar-CH₃), 3.65-3.75 (2H, m, Gly CH₂), 3.93 (2H, s, Gly CH₂), 3.98 (2H, s, Gly CH₂), 4.11 (2H, t, *J* = 6.6 Hz, CH₃(CH₂)₄CH₂CH₂O), 7.24 (2H, d, *J* = 8.1 Hz, Ar-H), 7.71 (2H, d, *J* = 8.1 Hz, Ar-H). ¹³C-NMR (CD₃OD): 14.5, 21.4, 23.8, 27.0, 29.8, 30.2, 33.0, 41.7, 42.1, 43.2, 66.6, 127.1, 130.0, 141.9, 143.6, 168.1, 171.4, 171.9. IR (nujol): cm⁻¹ 3336, 3263, 3110, 2922, 2853, 2719, 1740, 1706, 1685, 1651, 1594, 1547, 1499, 1461, 1412, 1377, 1368, 1313, 1232, 1214, 1175, 1128, 1037, 1014, 912, 816, 738, 724, 684.

Cbz-PGGG-OC₇H₁₅

General procedure 2. Quantities used: Cbz-L-Proline (1.08 g, 4.3 mmol) and TsOH-GGG-OC₇H₁₅ (2.0 g, 4.4 mmol). The crude product was chromatographed (silica gel, CH₃OH:CHCl₃ 98:2 95:5) to give colorless crystals (2.01 g, 90%), mp 94-96 °C. ¹H-NMR: 0.87 (3H, t, *J* = 6.9 Hz, CH₃(CH₂)₄CH₂CH₂O), 1.27 (8H, m, CH₃(CH₂)₄CH₂CH₂O), 1.60 (2H, bs, CH₃(CH₂)₄CH₂CH₂O), 1.75-2.20 (4H, m, Pro NCH₂CH₂CH₂), 3.45-3.60 (2H, m, Pro NCH₂CH₂CH₂), 3.75-4.00 (6H, Gly CH₂), 4.07 (2H, t, *J* = 6.6 Hz, CH₃(CH₂)₄CH₂CH₂O), 4.24 (1H, t, *J* = 6.3 Hz, Pro CH), 5.02-5.17 (2H, m, PhCH₂O), 7.00 (1H, bs, NH), 7.21 (1H, bs, NH), 7.33 (5H, m, Ar-H), 7.68 (1H, bs, NH). ¹³C-NMR: 14.0, 22.5, 25.7, 28.5, 28.8, 29.5, 31.6, 41.2, 43.0, 43.4, 47.1, 61.0, 65.5, 67.6, 127.8, 128.2, 128.5, 136.2, 156.0, 169.4, 169.7, 171.7, 173.3. IR (CHCl₃): cm⁻¹ 3310, 3068, 2955, 2931, 2858, 1749, 1669, 1541, 1419, 1360, 1206, 1125, 1091, 1030, 986, 919, 770, 731, 698.

PGGG-OC₇H₁₅

General procedure 3. Quantities used: Cbz-PGGG-OC₇H₁₅ (1.0 g, 1.9 mmol). Product: a white, waxy solid (0.74 g, 100%). ¹H NMR (CD₃OD): 0.91 (3H, t, *J* = 7.2 Hz, CH₃(CH₂)₄CH₂CH₂O), 1.32 (8H, m, CH₃(CH₂)₄CH₂CH₂O), 1.65 (2H, bs, CH₃(CH₂)₄CH₂CH₂O), 1.75-2.20 (4H, m, Pro NCH₂CH₂CH₂), 2.70-3.00 (2H, m, Pro NCH₂CH₂CH₂), 3.70-4.05 (7H, Gly CH₂, Pro CH), 4.13 (2H, t, *J* = 6.6 Hz, CH₃(CH₂)₄CH₂CH₂O). ¹³C-NMR (CD₃OD): 14.5, 22.3, 23.8, 26.1, 26.8, 27.0, 27.1, 27.4, 29.8, 30.2, 31.9, 33.0, 42.1, 43.5, 43.7, 43.8, 61.7, 64.3, 66.5, 171.0, 171.4, 172.0, 178.2. IR (nujol): cm⁻¹ 3284, 3177, 2921, 2855, 1740, 1653, 1461, 1377, 1155, 1077, 1029, 967, 892, 846, 770, 723.

18₂-[DGA]-GGGPGGG-OC₇H₁₅

General procedure 2. Quantities used: 18₂-[DGA]-GGG-OH (0.16 g, 0.2 mmol) and PGGG-OC₇H₁₅ (0.08 g, 0.2 mmol). Crude product was chromatographed (silica gel, CH₃OH:CHCl₃ 9:1 85:15) to give a white solid (0.14 g, 61%), mp 99-101 °C. ¹H NMR: 0.85-0.90 (9H, CH₃(CH₂)₁₅CH₂CH₂N, CH₃(CH₂)₄CH₂CH₂O), 1.24 (68H, m, CH₃(CH₂)₁₅CH₂CH₂N, CH₃(CH₂)₄CH₂CH₂O), 1.49 (4H, bs, CH₃(CH₂)₁₅CH₂CH₂N), 1.60 (2H, bs, CH₃(CH₂)₄CH₂CH₂O), 1.80-2.20 (4H, m, Pro NCH₂CH₂CH₂), 3.05 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 3.24 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 3.45-3.75 (2H, m, Pro NCH₂CH₂CH₂), 3.85-4.10 (16H, Gly CH₂, CH₃(CH₂)₄CH₂CH₂O, COCH₂O), 4.27 (2H, s, COCH₂O), 4.36 (1H, t, *J* = 6.6 Hz, Pro CH), 7.65 (2H, bs, NH), 7.89 (1H, bs, NH),

8.03 (1H, bs, NH), 8.26 (1H, bs, NH), 8.42 (1H, bs, NH). $^{13}\text{C-NMR}$: 14.0, 14.1, 22.6, 22.7, 25.1, 25.8, 26.9, 27.1, 27.6, 28.5, 28.8, 28.9, 29.1, 29.3, 29.4, 29.5, 29.6, 29.7, 31.7, 31.9, 41.2, 42.0, 42.8, 42.9, 43.4, 46.3, 61.3, 65.6, 69.4, 71.2, 168.5, 168.9, 170.2, 170.3, 170.4, 170.7, 171.2, 173.3. IR (CHCl_3): cm^{-1} 3308, 2920, 2851, 1744, 1652, 1540, 1467, 1376, 1338, 1209, 1129, 1109, 1031, 722. Anal. Calcd. for $\text{C}_{64}\text{H}_{118}\text{N}_8\text{O}_{11}\cdot\text{H}_2\text{O}$: C 64.40, H 10.13, N 9.39. Found: C 64.36, H 10.11, N 9.21.

$[\text{CH}_3(\text{CH}_2)_{17}]_2\text{NCOCH}_2\text{OCH}_2\text{CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-O-CH}_2\text{-c-C}_6\text{H}_{11}$, "C18-cyclohexylmethyl," 12

TsOH-GGG-OCH₂C₆H₁₁

GGG (2.0 g, 10.6 mmol) and *p*-TsOH·H₂O (2.2 g, 11.6 mmol) were added to cyclohexylmethanol (13.3 g, 116.4 mmol) and toluene (40 mL). The mixture was heated and water removed (reflux, Dean-Stark trap, 3h). The mixture was cooled to rt and evaporated, the residue was crystallized from CH₃OH:Et₂O methanol-ether (1:20 v:v) to give a white solid (4.80 g, 99%) mp 161-162 °C. $^1\text{H-NMR}$ (CD_3OD): 0.90-1.05 (2H, m, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.15-1.40 (3H, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.60-1.80 (6H, m, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 2.37 (3H, s, ArCH_3), 3.77 (2H, s, Gly CH₂), 3.92-3.96 (4H, s, $\text{OCH}_2\text{C}_6\text{H}_{11}$, CH₂ Gly CH₂), 3.98 (2H, s, Gly CH₂), 7.24 (2H, d, $J = 8.1$ Hz, Ar-H), 7.71 (2H, d, $J = 8.1$ Hz, Ar-H). $^{13}\text{C-NMR}$ (CD_3OD): 21.4, 26.9, 27.6, 30.8, 38.6, 41.8, 42.0, 42.1, 43.2, 71.4, 127.1, 130.0, 141.9, 168.1, 171.4, 171.9. IR (nujol): 3307, 2954, 2923, 2854, 1746, 1710, 1656, 1547, 1460, 1404, 1377, 1203, 1127, 1035, 1011, 984, 814, 722, 685 cm^{-1} .

BocPGGG-OCH₂C₆H₁₁

General procedure 2. Quantities used: Boc-L-Proline (0.47 g, 2.2 mmol), and TsOH-GGG-O-CH₂C₆H₁₁ (1.0 g, 2.2 mmol). Crude product was chromatographed (silica gel, eluant, CHCl₃:CH₃OH 98:2 95:5) which afforded a white solid (1.04 g, 99%), mp 69-70 °C. $^1\text{H-NMR}$: 0.85-1.00 (2H, m, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.05-1.35 (3H, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.41 (9H, s, $\text{C}(\text{CH}_3)_3$), 1.55-1.75 (6H, m, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.80-2.20 (4H, m, Pro NCH₂CH₂CH₂), 3.35-3.50 (2H, m, Pro NCH₂CH₂CH₂), 3.80-4.10 (8H, Gly CH₂, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 4.15 (1H, t, $J = 6.3$ Hz, Pro CH), 7.10 (1H, bs, NH), 7.28 (1H, bs, NH), 7.82 (1H, bs, NH). $^{13}\text{C-NMR}$: 24.6, 25.6, 26.2, 28.3, 28.5, 29.5, 36.9, 41.1, 43.0, 43.3, 45.9, 47.3, 60.7, 70.4, 80.8, 155.6, 169.4, 169.7, 169.9, 173.7. IR: cm^{-1} 3312, 3080, 2978, 2930, 2854, 1751, 1669, 1541, 1479, 1451, 1408, 1367, 1240, 1199, 1165, 1132, 1091, 1033, 983, 923, 889, 856, 755, 667.

PGGG-OCH₂Ph·HCl

General procedure 4. Quantities used: Boc-PGGG-OCH₂C₆H₁₁ (0.2 g, 0.4 mmol). The product was used in subsequent reaction without further purification.

18₂-[DGA]-GGGPGGG-OCH₂C₆H₁₁

General procedure 2. Quantities used: 18₂-[DGA]-GGG-OH (0.16 g, 0.2 mmol), and HCl-PGGG-OCH₂C₆H₁₁ (0.08 g, 0.2 mmol). Crude product was chromatographed (silica gel, CHCl₃:CH₃OH 9:1 85:15) to give the product as a white solid (0.14 g, 61%), mp 100-102 °C. $^1\text{H-NMR}$: 0.87 (8H, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.00-1.35 (63H, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.47 (4H, bs, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 1.50-1.60 (6H, m, $\text{OCH}_2\text{C}_6\text{H}_{11}$), 1.80-2.20 (4H, m, Pro NCH₂CH₂CH₂), 3.05 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 3.24 (2H, t, $J = 7.5$ Hz, $\text{CH}_3(\text{CH}_2)_{15}\text{CH}_2\text{CH}_2\text{N}$), 3.45-3.75 (2H, m, Pro NCH₂CH₂CH₂), 3.85-4.25 (18H, Gly CH₂, $\text{OCH}_2\text{C}_6\text{H}_{11}$, COCH₂O), 4.27 (2H, s, COCH₂O), 4.36 (1H, t, $J = 6.6$ Hz, Pro CH), 7.70 (2H, bs, NH), 7.90 (1H, bs, NH), 8.10 (1H, bs, NH), 8.42 (2H, bs, NH). $^{13}\text{C-NMR}$: 14.1, 22.7, 25.2, 25.6, 26.3, 26.9, 27.1, 27.6, 28.9, 29.0, 29.3, 29.4, 29.5, 29.6, 29.7, 37.0, 41.1, 42.0, 43.0, 43.5, 46.4, 47.0, 61.3, 69.6, 70.5, 71.5, 168.5,

168.9, 170.1, 170.2, 170.3, 170.4, 170.7, 171.1, 173.2 ppm. IR (CHCl₃): cm⁻¹ 3328, 3085, 2920, 2851, 1745, 1727, 1652, 1601, 1541, 1467, 1412, 1378, 1341, 1243, 1204, 1130, 1031, 909, 722. Anal. Calcd. for C₆₄H₁₁₆N₈O₁₁·H₂O: C 64.50, H 9.98, N 9.40. Found: C 64.34, H 9.93, N 9.47.

**[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-O(CH₂)₉CH₃,
“C18-decyl,” 13**

18₂-[DGA]-GGGPGGG-OC₁₀H₂₁

18₂-[DGA]-GGGPGGG-OH (0.20 g, 0.2 mmol) was suspended at 0° C in a mixture of CH₂Cl₂ (25 mL), DCCI (0.03 g, 0.2 mmol), DMAP (0.01 g, 0.1 mmol), and 1-decanol (0.03 g, 0.2 mmol). After stirring at rt for 48 h, the solvent was evaporated and the residue was chromatographed (silica gel, CHCl₃:CH₃OH 9:1) to give a white solid (0.13 g, 58%), mp 137-8 °C. ¹H-NMR: 0.80 (9H, m, CH₃), 1.17 (74H, m, NCH₂CH₂(CH₂)₁₅CH₃, OCH₂CH₂(CH₂)₇CH₃), 1.42-1.54 (6H, m, NCH₂CH₂(CH₂)₁₅CH₃, OCH₂CH₂(CH₂)₇CH₃), 1.85-2.2 (4H, m, Pro NCH₂CH₂CH₂), 3.00 (2H, t, *J* = 7.5 Hz, NCH₂CH₂(CH₂)₁₅CH₃), 3.19 (2H, t, *J* = 7.5 Hz, NCH₂CH₂(CH₂)₁₅CH₃), 3.45-3.60 (2H, m, Pro NCH₂CH₂CH₂), 3.7-4.1 (16 H, m, Gly CH₂, COCH₂O, OCH₂CH₂(CH₂)₇CH₃), 4.22 (2H, s, COCH₂O), 4.28 (1H, m, Pro CH), 7.34 (1H, t, *J* = 6.0 Hz, NH), 7.45 (1H, t, *J* = 6.0 Hz, NH), 7.81 (2H, m, NH), 7.98 (1H, t, *J* = 6.0 Hz, NH), 8.23 (1H, t, *J* = 6.0 Hz, NH). ¹³C-NMR: 14.3, 22.8, 25.3, 26.0, 27.1, 27.2, 27.8, 28.7, 29.0, 29.3, 29.48, 29.52, 29.6, 29.7, 29.8, 29.9, 32.1, 41.4, 42.0, 42.9, 43.0, 43.1, 46.5, 47.1, 61.4, 65.8, 69.6, 71.5, 168.5, 168.9, 170.3, 170.4, 170.5, 170.6, 170.9, 171.2, 173.7 ppm. Anal. Calcd. for C₆₇H₁₂₄N₈O₁₁·0.5H₂O: C 65.60, H 10.27, N 9.13. Found: C 65.53, H 10.24, N 9.03.

**[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-O(CH₂)₁₇CH₃,
“C18-octadecyl,” 14**

18₂-[DGA]-GGGPGGG-OC₁₈H₃₇

18₂-[DGA]-GGGPGGG-OH (0.20 g, 0.2 mmol), DCCI (0.04 g, 0.3 mmol), DMAP (0.01 g, 0.1 mmol), and 1-octadecanol (0.06 g, 0.2 mmol) were suspended in CH₂Cl₂ (25 mL) at 0° C. After stirring at rt for 48 h, the solvent was evaporated and the residue was crystallized from CH₃OH to give a white solid (0.20 g, 81%), mp 144-5 °C. ¹H-NMR: 0.80 (9H, m, CH₃), 1.18 (90H, m, NCH₂CH₂(CH₂)₁₅CH₃, OCH₂CH₂(CH₂)₁₅CH₃), 1.43 (4H, m, NCH₂CH₂(CH₂)₁₅CH₃), 1.54 (2H, bt, OCH₂CH₂(CH₂)₁₅CH₃), 1.8-2.2 (4H, m, Pro NCH₂CH₂CH₂), 3.00 (2H, t, *J* = 7.5 Hz, NCH₂CH₂(CH₂)₁₅CH₃), 3.19 (2H, t, *J* = 7.5 Hz, NCH₂CH₂(CH₂)₁₅CH₃), 3.42-3.65 (2H, m, Pro NCH₂CH₂CH₂), 3.7-4.1 (16 H, m, Gly CH₂, COCH₂O, OCH₂CH₂(CH₂)₁₅CH₃), 4.22 (2H, s, COCH₂O), 4.28 (1H, m, Pro CH), 7.32 (1H, bt, NH), 7.44 (1H, bt, NH), 7.81 (2H, m, NH), 7.85 (1H, bt, NH), 8.27 (1H, t, *J* = 6.0 Hz, NH). ¹³C-NMR: 14.3, 22.9, 25.4, 26.1, 27.1, 27.3, 27.8, 28.7, 29.1, 29.2, 29.6, 29.7, 29.8, 29.9, 30.0, 32.1, 41.4, 42.2, 43.1, 43.2, 43.7, 46.5, 47.1, 47.2, 61.5, 65.9, 69.8, 71.8, 168.6, 169.1, 170.3, 170.37, 170.44, 170.6, 170.9, 171.4, 173.5. Anal. Calcd. for C₇₅H₁₄₀N₈O₁₁·H₂O: C 66.83, H 10.62, N 8.31. Found: C 66.81, H 10.63, N 8.02.

**[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-NH (CH₂)₉CH₃,
“C18-decylamide” 15**

18₂-[DGA]-GGGPGGG-NHC₁₀H₂₁

General procedure 2. Quantities used: 18₂-[DGA]-GGGPGGG-OH (0.25 g, 0.2 mmol), and decylamine (0.04 g, 0.2 mmol). The crude product was chromatographed (silica gel,

CHCl₃:CH₃ 95:5 9:1) to give a white solid (0.10 g, 36%), mp 174-176 °C. ¹H-NMR: 0.86 (9H, t, *J* = 7.2 Hz, CH₃), 1.25 (74H, m, CH₃(CH₂)₁₅CH₂CH₂N and CH₃(CH₂)₇CH₂CH₂NH), 1.47 (6H, bs, CH₃(CH₂)₁₅CH₂CH₂N and CH₃(CH₂)₇CH₂CH₂NH), 1.90-2.30 (4H, m, Pro NCH₂CH₂CH₂), 3.07 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₁₆CH₂N), 3.15 (2H, t, *J* = 6.9 Hz, CH₃(CH₂)₈CH₂NH), 3.26 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₆CH₂N), 3.50-3.60 (1H, m, Pro NCH₂CH₂CH₂), 3.65-3.73 (1H, m, Pro NCH₂CH₂CH₂), 3.75-4.20 (14H, m, Gly CH₂, COCH₂O), 4.28 (2H, s, COCH₂O), 4.35 (1H, t, *J* = 7.5 Hz, Pro NCH), 7.18 (1H, *J* = 6.0 Hz, NH), 7.58 (1H, *J* = 6.0 Hz, NH), 7.85 (1H, *J* = 6.0 Hz, NH), 7.93 (1H, *J* = 6.0 Hz, NH), 7.95 (1H, *J* = 6.0 Hz, NH) 8.17 (1H, *J* = 6.0 Hz, NH), 8.29 (1H, bs, Gly NH). ¹³C-NMR: 14.10, 22.7, 25.1, 26.9, 27.0, 27.1, 27.6, 28.8, 29.1, 29.3, 29.4, 29.6, 29.7, 31.9, 39.6, 42.1, 42.8, 43.0, 43.5, 46.3, 46.9, 61.3, 69.3, 71.3, 168.3, 168.9, 169.3, 170.1, 170.3, 170.6, 170.7, 171.0, 173.2. IR (KBr): cm⁻¹ 3306, 3080, 2923, 2853, 1651, 1541, 1466, 1377, 1336, 1247, 1130, 1029, 721. Anal. Calcd for C₆₇H₁₂₅N₉O₁₀·H₂O: C 65.17, H 10.37, N 10.21. Found: C 65.16, H 10.29, N 10.16.

**CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-N [(CH₂)₉CH₃]₂,
“C18-didecylamide,” 16**

18₂-[DGA]-GGGPGGG-N(C₁₀H₂₁)₂

General procedure 2. Quantities used: 18₂-[DGA]-GGGPGGG-OH (0.25 g, 0.2 mmol), and didecylamine (0.07 g, 0.2 mmol). The crude product was chromatographed (silica gel, CHCl₃:CH₃OH 95:5 9:1) to give a white solid (0.12 g, 39%), mp 100-103 °C. ¹H-NMR: 0.87 (12H, t, *J* = 7.2 Hz, CH₃), 1.25 (84H, m, CH₃(CH₂)₁₅CH₂CH₂N, CH₃(CH₂)₆CH₂CH₂N), 1.50 (8H, bs, CH₃(CH₂)₁₅CH₂CH₂N, CH₃(CH₂)₆CH₂CH₂N), 1.90-2.25 (4H, m, Pro NCH₂CH₂CH₂), 3.07 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₁₆CH₂N), 3.15-3.40 (6H, CH₃(CH₂)₈CH₂NH, CH₃(CH₂)₁₆CH₂NH), 3.50-3.60 (1H, m, Pro NCH₂CH₂CH₂), 3.65-4.20 (15H, m, Gly CH₂, Pro NCH₂CH₂CH₂, COCH₂O), 4.29 (2H, s, COCH₂O), 4.38 (1H, t, *J* = 7.5 Hz, Pro NCH), 7.36 (1H, bs, NH), 7.70 (2H, m, NH), 7.76 (1H, bs, NH), 7.93 (1H, bs, NH), 8.40 (1H, bs, NH). ¹³C-NMR: 14.0, 14.1, 22.7, 25.1, 26.9, 27.1, 27.6, 27.7, 28.7, 28.9, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9, 41.1, 42.0, 42.9, 43.0, 43.1, 43.2, 46.3, 46.9, 47.0, 47.2, 61.3, 67.1, 69.6, 71.6, 167.4, 168.4, 169.1, 170.0, 170.1, 170.3, 171.2, 172.5. IR (KBr): cm⁻¹ 3304, 2925, 2852, 1651, 1541, 1465, 1376, 1334, 1245, 1129, 1030, 721 cm⁻¹. Anal. Calcd. for C₇₇H₁₄₅N₉O₁₀·H₂O: C 67.26, H 10.78, N 9.17. Found: C 67.25, H 10.71, N 9.18.

[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-NHC₁₈H₃₇, “C18-octadecylamide,” 17

18₂-[DGA]-GGGPGGG-NHC₁₈H₃₇

General procedure 2. Quantities used: 18₂-[DGA]-GGGPGGG-OH (0.25 g, 0.2 mmol), and octadecylamine (0.06 g, 0.2 mmol). The crude product was chromatographed (silica gel, CHCl₃:CH₃OH 95:5 9:1) to give a white solid (0.13 g, 42%), mp 168-170 °C. ¹H-NMR: 0.87 (9H, t, *J* = 7.2 Hz, CH₃), 1.24 (90H, m, CH₃(CH₂)₁₅CH₂CH₂N, CH₃(CH₂)₁₅CH₂CH₂NH), 1.46 (6H, bs, CH₃(CH₂)₁₅CH₂CH₂N, CH₃(CH₂)₇CH₂CH₂NH), 1.90-2.30 (4H, m, Pro NCH₂CH₂CH₂), 3.07 (2H, t, *J* = 7.8 Hz, CH₃(CH₂)₁₆CH₂N), 3.15 (2H, t, *J* = 6.9 Hz, CH₃(CH₂)₁₆CH₂NH), 3.26 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₆CH₂N), 3.50-3.60 (1H, m, Pro NCH₂CH₂CH₂), 3.65-4.20 (15H, m, Gly CH₂, Pro NCH₂CH₂CH₂, COCH₂O), 4.29 (2H, s, COCH₂O), 4.36 (1H, t, *J* = 7.5 Hz, Pro NCH), 7.18 (1H, *J* = 6.0 Hz, CONHC₁₈H₃₇), 7.61 (1H, *J* = 6.0 Hz, NH), 7.85 (1H, *J* = 6.0 Hz, NH), 7.94 (2H, m, NH), 8.18 (1H, t, *J* = 6.0 Hz, NH), 8.29 (1H, bs, NH). ¹³C-NMR: 14.0, 22.6, 25.0, 26.7, 26.8, 26.9, 27.4, 28.7, 29.0, 29.2, 29.6, 31.8, 39.5, 42.0, 42.6, 42.7, 42.8, 43.0, 46.2, 46.8, 46.9, 61.5, 68.9, 70.8, 168.3, 168.9, 169.2, 170.0, 170.5, 170.7, 171.3, 173.1. IR (CHCl₃): cm⁻¹ 3305, 3082, 2924, 2853, 1653, 1540, 1467,

1377, 1335, 1247, 1131, 1029, 720. Anal. Calcd. for $C_{75}H_{141}N_9O_{10} \cdot H_2O$: C 66.88, H 10.70, N 9.36. Found: C 67.07, H 10.71, N 9.33.

**[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-N [(CH₂)₆CH₃]₂,
“C18-diheptylamide,” 18**

Diheptylamine

A solution of *n*-heptylamine (5.0 g, 43.4 mmol), DMAP (0.4 g, 3.3 mmol), and NEt₃ (8.8 mL) in CH₂Cl₂ (60 mL) was cooled to 0 °C and a solution of heptanoyl chloride (6.5 g, 43.4 mmol) in CH₂Cl₂ (50 mL) was added dropwise. After stirring at rt for 24 h, the solvent was evaporated, the residue was dissolved in EtOAc, washed with 5% citric acid (250 mL), 5% NaHCO₃ dried over MgSO₄ and evaporated to give a white solid (9.55 g, 97%) mp 44-46 °C. ¹H-NMR: 0.85 (6H, t, *J* = 6.6 Hz, CH₃-), 1.26 (14H, pseudo-s, CH₃(CH₂)₄CH₂CH₂N, and CH₃(CH₂)₃CH₂CH₂CO), 1.46 (2H, m, CH₃(CH₂)₄CH₂CH₂N), 1.59 (2H, m, CH₃(CH₂)₃CH₂CH₂CO), 2.13 (2H, t, *J* = 7.7 Hz, CH₃(CH₂)₃CH₂CH₂CO), 3.20 (2H, m, CH₃(CH₂)₄CH₂CH₂N), 5.66 (1H, bs, NH). ¹³C-NMR: 14.0, 22.4, 22.5, 25.8, 26.8, 28.9, 29.6, 31.5, 31.7, 36.8, 39.4, 173.1. IR (CHCl₃): 3290, 3089, 2955, 2922, 2853, 1641, 1558, 1467, 1378, 1310, 1243, 1159, 947, 723 cm⁻¹.

C₆H₁₃CONHC₇H₁₅ (5.0 g, 22.0 mmol) dissolved in THF (15 mL) was added dropwise to LiAlH₄ (1.1 g, 29.0 mmol) suspended in dry THF (20 mL). The mixture was heated to reflux for 24 h, cooled, carefully diluted with water (1.1 mL) to decompose excess of LiAlH₄, followed by 15% NaOH (1.1 mL), and water (3.6 mL). The solid obtained after filtration was washed with Et₂O, and the solvent was evaporated. The residue was redissolved in Et₂O (50 mL), washed with brine (230 mL), dried over MgSO₄, and evaporated to give white solid (4.63 g, 99%) mp 30-1 °C. ¹H-NMR: 0.87 (6H, t, *J* = 6.6 Hz, CH₃(CH₂)₄CH₂CH₂NH), 1.27 (16H, pseudo-s, CH₃(CH₂)₄CH₂CH₂NH), 1.47 (4H, m, CH₃(CH₂)₄CH₂CH₂NH), 2.57 (4H, t, *J* = 7.2 Hz, CH₃(CH₂)₄CH₂CH₂NH). ¹³C-NMR: 14.0, 22.6, 27.4, 29.2, 30.2, 31.8, 50.1. IR (CHCl₃): cm⁻¹ 3400, 2957, 2926, 2855, 1466, 1378, 1130, 724 cm⁻¹.

18₂-[DGA]-GGGPGGG-N(C₁₈H₃₇)₂

General procedure 2. Quantities used: 18₂[DGA]-GGGPGGG-OH (0.24 g, 0.22 mmol), and diheptylamine (0.05 g, 0.23 mmol). The crude product was chromatographed (silica gel, CHCl₃:CH₃OH 95:5) to give a colorless oil (0.21 g, 75%). ¹H-NMR: 0.80-0.94 (12H, m, CH₃), 1.25 (68H, pseudo-s, CH₃(CH₂)₁₅CH₂CH₂N and CH₃(CH₂)₄CH₂CH₂NH), 1.47 (8H, bs, CH₃(CH₂)₁₅CH₂CH₂N and CH₃(CH₂)₇CH₂CH₂NH), 1.90-2.30 (4H, m, Pro NCH₂CH₂CH₂), 3.07 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₆CH₂N), 3.17 (4H, t, *J* = 7.0 Hz, CH₃(CH₂)₅CH₂NH), 3.27 (2H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₆CH₂N), 3.50-3.60 (1H, m, Pro NCH₂CH₂CH₂), 3.65-3.73 (1H, m, Pro NCH₂CH₂CH₂), 3.75-4.20 (14H, m, Gly NCH₂, and COCH₂O), 4.28 (2H, s, COCH₂O), 4.39 (1H, bs, Pro NCH), 7.39 (1H, bs, Gly CONH), 7.72 (1H, bs, Gly CONH), 7.77 (1H, bs, Gly CONH), 7.89 (1H, bs, Gly CONH), 7.96 (1H, bs, Gly CONH) 8.37 (1H, bs, Gly CONH). ¹³C-NMR: 14.0, 14.1, 22.5, 22.6, 22.7, 25.1, 26.8, 26.9, 27.0, 27.1, 27.6, 28.7, 28.8, 28.9, 29.1, 29.3, 29.4, 29.5, 29.6, 29.7, 31.7, 31.9, 41.1, 41.9, 42.9, 43.2, 46.3, 47.1, 61.3, 69.5, 71.5, 167.5, 168.4, 169.0, 170.1, 170.4, 171.1, 172.7. IR (CHCl₃): cm⁻¹ 3307, 2919, 2851, 1651, 1544, 1467, 1378, 1246, 1129, 1028, 721. Anal. Calcd for C₇₁H₁₃₃N₉O₁₀: C, 67.00; H, 10.53; N, 9.90 %. Found: C, 67.00; H, 10.53; N, 9.90 %.

[CH₃(CH₂)₁₇]₂NCOCH₂OCH₂CO-Gly-Gly-Gly-Pro-Gly-Gly-Gly-N [(CH₂)₁₇CH₃]₂, “C18-dioctadecylamide,” 19

18₂-[DGA]-GGGPGGG-N(C₁₈H₃₇)₂

General procedure 2. Quantities used: 18₂-[DGA]-GGGPGGG-OH (0.21 g, 0.2 mmol), and dioctadecylamine (0.10 g, 0.2 mmol). The crude product was chromatographed (silica gel, CHCl₃:CH₃OH 95:5 85:15) and crystallized from CH₃OH to give a white solid (0.10 g, 32%), mp 152-3 °C. ¹H-NMR: 0.87 (12H, t, *J* = 6.6 Hz, CH₃), 1.25 (120H, m, CH₃(CH₂)₁₅CH₂CH₂N), 1.51 (4H, bs, CH₃(CH₂)₁₅CH₂CH₂NCOCH₂O), 1.61 (4H, bt, CH₃(CH₂)₁₅CH₂CH₂NCOCH₂N), 1.90-2.25 (4H, m, Pro NCH₂CH₂CH₂), 3.07 (4H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 3.27 (4H, t, *J* = 7.5 Hz, CH₃(CH₂)₁₅CH₂CH₂N), 3.47-3.77 (2H, m, Pro NCH₂CH₂CH₂), 3.80-4.15 (16H, m, Gly CH₂, COCH₂O), 4.29 (2H, s, COCH₂O), 4.37 (1H, t, *J* = 7.5 Hz, Pro NCH), 7.40 (1H, bt, NH), 7.54 (1H, bt, NH), 7.90 (3H, m, NH), 8.41 (1H, bs, NH). ¹³C-NMR: 14.3, 22.9, 25.4, 26.1, 27.1, 27.3, 27.8, 28.7, 29.1, 29.3, 29.6, 29.7, 29.9, 32.1, 41.5, 42.2, 43.2, 43.7, 46.6, 47.2, 61.6, 65.9, 69.7, 71.7, 168.7, 169.2, 170.32, 170.35, 170.5, 170.7, 171.0, 171.5, 173.5. Anal. Calcd. for C₉₃H₁₇₇N₉O₁₀: C 70.63, H 11.28, N 7.97. Found: C 70.63, H 11.28, N 7.97.

Formation of vesicles

1,2-Dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-*sn*-glycero-3-phosphate (DOPA) were obtained from Avanti Polar Lipids as CHCl₃ solutions (vials with 25 mg in 2.5 mL). Dry lipid films of DOPC-DOPA (20 mg, 7:3 w/w) were dissolved in Et₂O (0.5 mL) and then 0.5 mL of internal buffer (600 mM KCl:10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), pH adjusted to 7.0) were added. The mixture was sonicated for approximately 10 s to give an opalescent dispersion. The organic solvent was then removed by evaporation under mild vacuum at 30 °C. The suspension was filtered through a 200 nm filter membrane (5 times) using a mini extruder and passed through a Sephadex G25 column, which had been equilibrated with external buffer (400 mM K₂SO₄:10 mM HEPES, pH adjusted to 7.0). The vesicles collected were subsequently characterized using laser light scattering, and their diameter was consistently ~200 nm, as measured by a Coulter N4MD submicron particle analyzer. The final lipids concentration was assessed through colorimetric determination of the phospholipid-ammonium ferrothiocyanate complex.⁴⁶

Studies of chloride release from liposomes

Chloride release was assayed directly on 200 nm, 0.23 mM phospholipid vesicles by using a chloride selective electrode (Accumet Chloride Combination Electrode). The electrode was introduced in a 2 mL vesicles solution and allowed to equilibrate. The voltage output was recorded, and after five minutes, aliquots of the solution of compound at study (~9 mM in 2-propanol) were added. No more than 20 μL of 2-propanol were added in any experiment in order to avoid any effect of the solvent on the liposomes. Complete lysis of the vesicles was induced by addition of a 2 % aqueous solution of Triton X100 (100 μL) and the data collected were normalized to this value. The data were collected using a DigiData 1322A series interface and Axoscope 9.0 software.

Carboxyfluorescein Dequenching from Unilamellar Liposomes

Liposomes were prepared using the reverse phase procedure of Szoka and Papahadjopoulos.⁴⁷ A lipid mixture (10 mg composed of 30% 1,2-dioleoyl-*sn*-glycero-3-phosphate and 70% 1,2-dioleoyl-*sn*-glycero-3-phosphocholine, Avanti Polar Lipids, AL) was dissolved in 0.5 mL of Et₂O. To this was added 0.5 mL of 20 mM carboxyfluorescein in 100 mM KCl:10 mM HEPES (pH=7.0) and the final pH was adjusted to 7.0 with KOH. This mixture was sonicated at 1200 W for 30 seconds at 20 °C to produce a stable emulsion. The Et₂O was removed

(water aspirator, 15 °C) in a round bottom flask rotating at 40 rpm. The 0.5 mL suspension was supplemented with an additional 0.5 mL of 20 mM carboxyfluorescein solution. This mixture was passed (five times) through a 200 nm nucleopore filter. The extra-vesicular carboxyfluorescein was removed by passing the liposome-dye mixture over a 120 cm Sephacryl G-25 column (Sigma) in 100 mM KCl: 10 mM HEPES (pH=7.0). The liposome peak was collected and analyzed by dynamic light scattering, diameter = 182 ± 12 nm. Phospholipid concentration in this fraction was determined to be 3.3 mg/mL.⁴⁵

Prior to use, carboxyfluorescein-containing vesicles were diluted to 0.66 $\mu\text{g/mL}$ in a reaction volume of 500 μL . The fluorescence (excitation 497 nm: emission 520 nm at 2 nm bandpass) was monitored at 25 °C. Compounds were added as a 5 mM solution in 2-propanol with mixing to the indicated concentrations. Data were digitized at 10 points per second and subsequently reduced to one point per second by decimation. Dequenching, F_{520} , was computed as the fraction of total release upon addition of 1% Triton X100:

$$F_{520} = \frac{F - F_0}{F_{\text{Triton}} - F_0} \quad (1)$$

with F_0 and F_{Triton} being the zero time and the fluorescence produced in the presence of Triton X-100. Dequenching data were fit using a nonlinear least squares method based upon the Levenberg-Marquardt algorithm, which generated χ^2 values indicating the goodness of fit, for each group of averaged data sets. The number of individual trials generating the data set (degrees of freedom) was used to obtain the p value for the individual fits and kinetic constants. In all cases, the χ^2 values for individual fits were less than 0.05 and the resulting p values varied from 0.05 to 0.001 depending upon the number of trials. Data were fit to the equation,

$$F_{520} = F_0 + A_1 (1 - e^{-\text{time}/\tau}) + m \cdot \text{time}, \quad (2)$$

as described previously.^{39,48} In this equation, F_0 is the fluorescence at time zero, A_1 is the size of the exponential component, τ is the time constant for pore activation, and m is the slope of the linear dequenching resulting from multiple pores per vesicle.

Notes and References

- 1(a). Aidley, DJ.; Stanfield, PR. *Ion Channels: Molecules in Action*. Cambridge University Press; Cambridge: 1996. Hille, B. *Ionic Channels of Excitable Membranes* (Third Edition). Vol. 3rd Edn.. Sinauer Associates; Sunderland, MA: 2001.
- 2(a). Doyle DA, Cabral JM, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. *Science* 1998;280:69–77. [PubMed: 9525859] (b) MacKinnon R, Cohen SL, Kuo A, Lee A, Chait BT. *Science* 1998;280:106–109. [PubMed: 9525854]
3. Sato C, Ueno Y, Asai K, Takahashi K, Sato M, Engel A, Fujiyoshi Y. *Nature* 2001;409:1047–1051. [PubMed: 11234014]
- 4(a). Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R. *Nature* 2002;415:287–294. [PubMed: 11796999] (b) Dutzler R, Campbell EB, MacKinnon R. *Science* 2003;300:108–112. [PubMed: 12649487]
- 5(a). Preston GM, Carroll TP, Guggino WB, Agre P. *Science* 1992;256:385–387. [PubMed: 1373524] (b) Borghnia M, Nielsen S, Engel A, Agre P. *Annu Rev Biochem* 1999;68:425–458. [PubMed: 10872456] (c) Hummer G, Rasalah JC, Noworyta JP. *Nature* 2001;414:188–190. [PubMed: 11700553]
- 6(a). Chang G, Spencer RH, Lee AT, Barclay MT, Rees DC. *Science* 1998;282:2220–2226. [PubMed: 9856938] (b) Spencer RH, Chang G, Rees DC. *Curr. Opin. Struct. Biol* 1999;9:448–454. [PubMed: 10872456]

- 10449367] (c) Scarsdale JN, Kazanina G, He X, Reynolds KA, Wright HT. *J. Biol. Chem* 2001;276:20516–20522. [PubMed: 11278743]
7. Agre P. *Angew. Chem. Int. Ed. Engl* 2004;43:4278–90. [PubMed: 15368374]
8. MacKinnon R. *Angew Chem Int Ed Engl* 2004;43:4265–77. [PubMed: 15368373]
- 9(a). Reusch RN, Sadoff HL. *Proc. Natl. Acad. Sci* 1988;85:4176–4180. [PubMed: 2454464] (b) Reusch RN, Huang R, Bramble LL. *Biophys. J* 1995;69:754–766. [PubMed: 8519976]
- 10(a). Seebach D, Brunner A, Buegger HM, Reusch RN, Bramble LL. *Helv. Chim. Acta* 1996;79:507–517. (b) Das S, Lengweiler UD, Seebach D, Reusch RN. *Proc. Nat. Acad. Sci. (USA)* 1997;94:9075–9079. [PubMed: 9256437]
- 11(a). Oiki S, Danho W, Montal M. *Proc. Natl. Acad. Sci.(USA)* 1988;85:2393–2397. [PubMed: 2451248] (b) Montal M, Montal MS, Tomich JM. *Proc. Nat. Acad. Sci. (USA)* 1990;87:6929–6933. [PubMed: 1698285]
- 12(a). Iwamoto T, Grove A, Montal MO, Montal M, Tomich JM. *nt. J. Pept. Protein. Res* 1994;43:597–607. (b) Montal M. *Annu. Rev. Biophys. Biomol. Struct* 1995;24:31–57. [PubMed: 7663119]
- 13(a). Lear JD, Wasserman ZR, DeGrado WF. *Science* 1988;240:1177–1181. [PubMed: 2453923] (b) DeGrado WF, Wasserman ZR, Lear JD. *Science* 1989;243:622–628. [PubMed: 2464850]
- 14(a). Åkerfeldt KS, Lear JD, Wasserman ZR, Chung LA, DeGrado WF. *Acc. Chem. Res* 1993;26:191–197. (b) Dieckmann GR, DeGrado WF. *Curr. Opin. Struct. Biol* 1997;7:486–494. [PubMed: 9266169]
15. Tabushi I, Kuroda Y, Yokota K. *Tetrahedron Lett* 1982:4601–4604.
16. Carmichael VE, Dutton PJ, Fyles TM, James TD, Swan JA, Zojaji M. *J. Am. Chem. Soc* 1989;111:767–769.
17. Jullien L, Lehn J-M. *Tetrahedron Lett* 1988:3803–3806.
18. Menger FM, Davis DS, Persichetti RA, Lee J-J. *J. Am. Chem. Soc* 1990;112:2451–2452.
- 19(a). Beijnen, A. J. M. v.; Nolte, RJM.; Zwikker, JW.; Drenth, W. *Recl. Trav. Pays-Bas* 1982;101:409–410. (b) Roks MFM, Nolte RJM. *Macromolecules* 1992;25:5398–5407.
20. Kobuke Y, Ueda K, Sokabe M. *J. Am. Chem. Soc* 1992;114:7618–7822.
21. Nakano A, Xie Q, Mallen JV, Echegoyen L, Gokel GW. *J. Am. Chem. Soc* 1990;112:1287–1289.
22. Meillon J-C, Voyer N. *Angew. Chem. Int. Ed. Engl* 1997;36:967–969.
23. Sakai N, Ni C, Bezrukov SM, Matile S. *Bioorg. Med. Chem. Lett* 1998;8:2743–2746. [PubMed: 9873614]
24. Schrey A, Vescovi A, Knoll A, Rickert C, Koert U. *Angew. Chem. Int. Ed* 2000;39:900–902.
- 25(a). Gokel GW, Murillo O. *Acc. Chem. Res* 1996;29:425–432. (b) Gokel GW, Mukhopadhyay A. *Chem. Soc. Reviews* 2001;30:274–286.
26. Boon JM, Smith BD. *Curr Opin Chem Biol* 2002;6:749–756. [PubMed: 12470727]
27. Bell TW. *Curr. Opin. Chem. Biol* 1998;2:711–716. [PubMed: 9914195]
28. Sakai N, Matile S. *Chem. Commun* 2003:2514–2523.
29. Bianchi, A.; Bowman-James, K.; Garcia-España, E. *Supramolecular Chemistry of Anions*. Wiley-VCH; New York: 1997.
- 30(a). Wallace DP, Tomich JM, Eppler JW, Iwamoto T, Grantham JJ, Sullivan LP. *Biochim. Biophys. Acta* 2000;1464:69–82. [PubMed: 10704921] (b) Broughman JR, Mitchell KE, Sedlacek RL, Iwamoto T, Tomich JM, Schultz BD. *Am. J. Physiol* 2001;280:C451–C458. (c) Gao L, Broughman JR, Iwamoto T, Tomich JM, Venglarik CJ, Forman HJ. *Am. J. Physiol* 2001;281:L24–L30.
31. Sidorov V, Kotch FW, Kuebler JL, Lam Y-F, Davis JT. *J. Am. Chem. Soc* 2003;125:2840–2841. [PubMed: 12617627]
- 32(a). Schlesinger PH, Ferdani R, Liu J, Pajewska J, Pajewski R, Saito M, Shabany H, Gokel GW. *J. Am. Chem. Soc* 2002;124:1848–1849. [PubMed: 11866586] (b) Schlesinger PH, Ferdani R, Pajewski R, Pajewska J, Gokel GW. *Chem. Comm* 2002:840–841. [PubMed: 12123005] (c) Schlesinger PH, Djedovic NK, Ferdani R, Pajewska J, Pajewski R, Gokel GW. *Chem. Comm* 2003:308–309. [PubMed: 12613586] (d) Schlesinger PH, Ferdani R, Pajewska J, Pajewski R, Gokel GW. *New J. Chem* 2003;27:60–67.
33. Sakai N, Houdebert D, Matile S. *Chemistry* 2003;9:223–232. [PubMed: 12506379]

34. Gokel GW. *Chem. Comm* 2000:1–9.
35. Bolard J. *Biochim. Biophys. Acta* 1986;864:257–304. [PubMed: 3539192]
36. Zhou J, Lu X, Wang Y, Shi J. 2002;194-197:257–270.
37. Hervé M, Cybulska B, Gary-Bobo CM. *Eur. Biophys. J* 1985;12:121–128.
- 38(a). Carmichael VE, Dutton PJ, Fyles TM, James TD, Swan JA, Zojaji M. *J. Am. Chem. Soc* 1989;111:767–769. (b) Fyles TM, James TD, Kaye KC. *J. Am. Chem. Soc* 1993;115:12315–12321.
39. Riddell FG, Tompsett SJ. *Biochim. Biophys. Acta* 1990;990:193–197. [PubMed: 2337616]
40. Murillo O, Watanabe S, Nakano A, Gokel GW. *J. Am. Chem. Soc* 1995;117:7665–7679.
41. Saito M, Korsmeyer SJ, Schlesinger PH. *Nature Cell Biology* 2000:553–555.
42. Koulov AV, Lambert TN, Shukla R, Jain M, Boon JM, Smith BD, Li H, Sheppard DN, Joos JB, Clare JP, Davis AP. *Angew. Chem. Int. Ed. Engl* 2003;42:4931–4933. [PubMed: 14579442]
43. Ladokhin AS, Selsted ME, White SH. *Biophys. J* 1997;72:1762–1766. [PubMed: 9083680]
44. Hernandez JC, Trafton JE, Gokel GW. *Tetrahedron Lett* 1991:6269–6272.
45. Huang HW, Chen F-Y, Lee M-T. *Phys. Rev. Lett* 2004;92:198304/1–198304/4. [PubMed: 15169456]
46. Stewart JCM. *Anal. Chem* 1980;104:10–14.
47. Szoka F, Papahadjopoulos D. *Proc. Natl. Acad. Sci. (USA)* 1978;75:4194–4198. [PubMed: 279908]
48. Rex S, Schwarz G. *Biochem* 1998;37:2336–2345. [PubMed: 9485380]




Figure 1.
Molecular model of H₂N-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OCH₃ obtained by energy minimization in Gaussian 98W.




Figure 2. Calculated octanol:water partition coefficients (logP) for (top panel) 1-8 and (lower panel) 8-14.




Figure 3. Fractional chloride ion release from 200 nm phospholipid vesicles mediated by compounds 1-8.




Figure 4. Carboxyfluorescein release from 200 nm phospholipid vesicles mediated by compounds 3-8.




Figure 5. Data for the pore stoichiometry and sizes obtained from carboxyfluorescein release from liposomes mediated by (left panels) **8** and (right panels) **4**.




Figure 6. Fractional chloride release from 200 nm phospholipid vesicles mediated by $(C_{18})_2NCOCH_2OCH_2CON-GGGPGGG-OR$, *i.e.*, compounds **8-14**




Figure 7. Anion transport by C18-heptyl ester (**11**). Upper panel: Fractional chloride ion release by **11** at (from bottom to top) 34, 50, 67, 84, 101, 117, and 134 μM . Lower panel: Fractional carboxyfluorescein release by **11** at (from bottom to top) 1.95, 4.85, 9.80, and 27.8 μM .




Figure 8. Fractional chloride release from 200 nm phospholipid vesicles mediated by $(C_{18})_2NCOCH_2OCH_2CON-GGGPGGG-NR^1R^2$, *i.e.*, compounds **15-19**.





Figure 9. Schematic representation of two molecules of $(C_{18})_2NCOCH_2OCH_2CON-GGGPGGG-OR$ in one bilayer leaflet.



Scheme 1.

Table 1C-Terminal derivatives of $R_2NCOCH_2OCH_2CONH-Gly-Gly-Gly-Pro-Gly-Gly-Gly-OR'$ (NHR' or NR'₂)

<i>Cpd. No.</i>	<i>Short name used in text</i>	<i>N-Terminal group (NHR' or NR'₂)</i>	<i>C-Terminal group, OR' or NRR'</i>
1	C3-benzyl	$[CH_3(CH_2)_2]_2N$	$OCH_2C_6H_5$
2	C6-benzyl	$[CH_3(CH_2)_5]_2N$	$OCH_2C_6H_5$
3	C8-benzyl	$[CH_3(CH_2)_7]_2N$	$OCH_2C_6H_5$
4	C10-benzyl	$[CH_3(CH_2)_9]_2N$	$OCH_2C_6H_5$
5	C12-benzyl	$[CH_3(CH_2)_{11}]_2N$	$OCH_2C_6H_5$
6	C14-benzyl	$[CH_3(CH_2)_{13}]_2N$	$OCH_2C_6H_5$
7	C16-benzyl	$[CH_3(CH_2)_{15}]_2N$	$OCH_2C_6H_5$
8	C18-benzyl	$[CH_3(CH_2)_{17}]_2N$	$OCH_2C_6H_5$
9	C18-ethyl	$[CH_3(CH_2)_{17}]_2N$	OCH_2CH_3
10	C18-isopropyl	$[CH_3(CH_2)_{17}]_2N$	$OCH(CH_3)_2$
11	C18-heptyl	$[CH_3(CH_2)_{17}]_2N$	$O(CH_2)_6CH_3$
12	C18-cyclohexylmethyl	$[CH_3(CH_2)_{17}]_2N$	$OCH_2C_6H_{11}$
13	C18-decyl	$[CH_3(CH_2)_{17}]_2N$	$O(CH_2)_9CH_3$
14	C18-octadecyl	$[CH_3(CH_2)_{17}]_2N$	$O(CH_2)_{17}CH_3$
15	C18-diheptylamide	$[CH_3(CH_2)_{17}]_2N$	$N[(CH_2)_6CH_3]_2$
16	C18-decylamide	$[CH_3(CH_2)_{17}]_2N$	$NH(CH_2)_9CH_3$
17	C18-didecylamide	$[CH_3(CH_2)_{17}]_2N$	$N[(CH_2)_9CH_3]_2$
18	C18-octadecylamide	$[CH_3(CH_2)_{17}]_2N$	$NH(CH_2)_{17}CH_3$
19	C18-dioctadecylamide	$[CH_3(CH_2)_{17}]_2N$	$N[(CH_2)_{17}CH_3]_2$